Camrelizumab Clinical Trials (2026): 410 Studies for Hepatocellular Carcinoma & Nasopharyngeal Carcinoma
Hipa.ai Research · Source: ClinicalTrials.gov / AACT
Synced daily from ClinicalTrials.gov via AACT. Last sync: .
410 Camrelizumab clinical trials are catalogued on Hipa.ai from the AACT mirror of ClinicalTrials.gov, spanning 224 indications (including Hepatocellular Carcinoma & Nasopharyngeal Carcinoma) and 46,153 total planned enrollment. 44 Phase 3 Camrelizumab trials and 261 Phase 2, 1 Phase 4 are listed. 139 Camrelizumab clinical trials are actively recruiting. Most recent activity: NCT05981001 (Apr 2035).
Camrelizumab clinical trials at a glance: phase × recruitment status
| Phase | recruiting | active not recruiting | enrolling by invitation | completed | terminated | withdrawn | suspended | not yet recruiting | unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Early P1 | 1 | 1 | 2 | |||||||
| P1 | 2 | 1 | 2 | 1 | 1 | 10 | 17 | |||
| P1/P2 | 5 | 2 | 1 | 1 | 3 | 18 | 30 | |||
| P2 | 53 | 10 | 3 | 21 | 2 | 1 | 26 | 145 | 261 | |
| P2/P3 | 4 | 2 | 3 | 4 | 13 | |||||
| P3 | 20 | 5 | 3 | 4 | 2 | 10 | 44 | |||
| P4 | 1 | 1 | ||||||||
| N/A | 11 | 2 | 1 | 4 | 24 | 42 |
Recruiting Camrelizumab clinical trials (139)
Studies currently enrolling participants. Click any NCT ID to view the trial detail page (eligibility, sites, contacts).
| NCT ID | Title | Phase | Indication | Enrollment | Started |
|---|---|---|---|---|---|
| NCT05981001 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | P1/P2 | Breast Neoplasms | 170 | Aug 2023 |
| NCT07521605 | Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer | P2 | Rectal Cancer Patients | 44 | May 2026 |
| NCT07505186 | Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma | P2 | Esophageal Squamous Cell Carcinoma | 45 | May 2026 |
| NCT07432087 | Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | P3 | Head and Neck Squamous Cell Carcinoma | 246 | Feb 2026 |
| NCT04803539 | ArtemisA Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC | P2/P3 | Breast Cancer | 260 | Apr 2021 |
| NCT07267806 | Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC | P3 | Hepato Cellular Carcinoma (HCC) | 326 | Oct 2025 |
| NCT06831175 | Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma | P2 | Adrenal Cortical Carcinoma | 28 | Mar 2025 |
| NCT06121557 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | P1 | Breast Neoplasms | 24 | Nov 2023 |
| NCT06561308 | Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer | P2 | Endometrioid Endometrial Cancer | 39 | Sep 2025 |
| NCT06288373 | Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC | P2/P3 | Cervical Cancer | 440 | Apr 2024 |
| NCT06533384 | PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC | P3 | Triple-negative Breast Cancer | 310 | Aug 2024 |
| NCT05043688 | Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. | P3 | Resectable Esophageal Squamous Cell Carcinoma | 426 | Sep 2021 |
| NCT07266350 | A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer | — | Cervical Cancer Metastatic | 1,300 | Dec 2025 |
| NCT06288360 | Neoadjuvant Immunochemotherapy in PD-L1-negative LACC | P2 | Cervical Cancer | 40 | Sep 2024 |
| NCT07057089 | Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) | P2 | Locally Advanced Rectal Cancer | 90 | Jul 2025 |
| NCT06289062 | Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer | P2 | Cervical Cancer | 40 | May 2024 |
| NCT06335355 | A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | P2/P3 | Non-squamous Non-small Cell Lung Cancer | 401 | Mar 2024 |
| NCT07466901 | A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer | N/A | Cervical Cancer | 30 | Apr 2026 |
| NCT07309419 | Cocktail-001A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma | P2/P3 | Hepatocellular Carcinoma | 222 | Dec 2025 |
| NCT07026149 | Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer | P2 | Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma | 30 | Jun 2025 |
| NCT06796803 | HAICCamrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) | P2/P3 | Potentially Resectable Hepatocellular Carcinoma | 398 | Feb 2025 |
| NCT06215677 | NITDCNeoadjuvant Immunotherapy for T4 dMMR Colon Cancer | N/A | Colon Cancer | 18 | Jan 2024 |
| NCT07555860 | Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | P2 | Nasopharyngeal Carcinoma | 28 | Apr 2026 |
| NCT07191977 | Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma | P2 | Esophageal Squamour Cell Cancer | 41 | Jan 2026 |
| NCT06869226 | A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer | P2 | Esophageal Cancer | 283 | Apr 2025 |
| NCT07167160 | Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial | P2 | Cervical Cancer | 59 | Mar 2025 |
| NCT06692491 | SPRINGStudy of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | P2 | Rare Tumour | 200 | Jan 2025 |
| NCT06669611 | Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | P3 | Nasopharyngeal Cancinoma (NPC) | 242 | Nov 2024 |
| NCT06229041 | Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) | P3 | Rectal Cancer | 472 | Mar 2023 |
| NCT05582499 | FASCINATE-NFudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | P2 | Breast Neoplasm | 716 | Nov 2022 |
| NCT06172205 | Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | P3 | BCLC Stage C Hepatocellular Carcinoma | 262 | Jul 2023 |
| NCT07589244 | A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC | P2/P3 | HCC | 66 | May 2026 |
| NCT06889688 | Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | P3 | Breast Cancer Stage IV | 246 | Feb 2025 |
| NCT06438627 | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial | P3 | Nasopharyngeal Carcinoma | 164 | May 2024 |
| NCT05825443 | PANORAMAAdjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients | P2 | Immunotherapy | 57 | Apr 2023 |
| NCT07400094 | NeoCamre-HNNeoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC | P2 | Squamous Cell Carcinoma of Head and Neck | 50 | Feb 2026 |
| NCT07527026 | A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer | P2 | Locally Advanced Rectal Cancer | 44 | Feb 2026 |
| NCT07395063 | A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. | P2 | Metastatic Colorectal Cancer (CRC) | 68 | Feb 2026 |
| NCT07328009 | HCC-SIGHTA Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma | P2 | Hepato Cellular Carcinoma (HCC) | 350 | Jan 2026 |
| NCT07324473 | Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study | P2 | Hepatocellular Carcinomas | 65 | Jan 2026 |
| NCT07314372 | FAD-HCC-001FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma | P2 | Unresectable Hepatocellular Carcinoma (HCC) | 86 | Feb 2026 |
| NCT06849492 | SHIFT-001HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer | P2 | Advanced Triple Negative Breast Cancer | 120 | Apr 2025 |
| NCT05749588 | FUSCC Refractory TNBC Platform Study (FUTURE2.0) | P2 | Triple-negative Breast Cancer | 120 | Mar 2023 |
| NCT05761470 | IMPARPNeoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation | P2 | Her-2 Negative Breast Cancer | 66 | May 2022 |
| NCT04453826 | Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma | P3 | Nasopharyngeal Cancer | 388 | Sep 2020 |
| NCT07147101 | HCC-IM-1Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment | — | Advanced Hepatocellular Carcinoma (HCC) | 150 | Sep 2025 |
| NCT07105748 | TASK-05HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) | P2 | Mixed Hepatocellular-cholangiocarcinoma | 45 | Aug 2025 |
| NCT07100392 | LEAF-02Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab | P2 | Hepatocellular Carcinoma (HCC) | 141 | Aug 2025 |
| NCT06145308 | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing | P2 | Salivary Gland Carcinoma | 39 | Aug 2023 |
| NCT07143292 | A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer | P2 | Cervical Cancer Metastatic | 120 | Nov 2025 |
| NCT06485466 | TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | P3 | Unresectable Hepatocellular Carcinoma | 101 | Aug 2024 |
| NCT05069857 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | P2 | Oral Squamous Cell Carcinoma | 46 | Sep 2021 |
| NCT06759090 | Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer | P2 | Metastatic Pancreatic Carcinoma | 43 | Jan 2025 |
| NCT04944914 | Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma | P3 | Nasopharyngeal Carcinoma | 188 | Jun 2021 |
| NCT07159217 | Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer | P2 | Biliary Tract Cancer | 65 | Aug 2025 |
| NCT06361888 | A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | P2/P3 | Metastatic Pancreatic Cancer | 502 | May 2024 |
| NCT06163729 | Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma | P2 | Gastroesophageal Junction Adenocarcinoma (Siewert II-III) | 68 | Aug 2022 |
| NCT06360042 | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | P2 | Unresectable Hepatocellular Carcinoma | 111 | Jan 2024 |
| NCT06745193 | A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer | P2 | Advanced Esophageal Carcinoma | 63 | Feb 2025 |
| NCT06607107 | mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria | P2 | Hepatocellular Carcinoma Non-resectable | 29 | Feb 2024 |
| NCT06196671 | PTCA199-8Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer | P2 | Pancreatic Cancer | 30 | Dec 2026 |
| NCT05772208 | Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy | P3 | Nasopharyngeal Carcinoma | 459 | Jan 2022 |
| NCT07161791 | Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer | P1/P2 | Breast Cancer | 12 | Sep 2025 |
| NCT07107217 | CamellaCamrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer | P2 | Breast Cancer | 40 | Aug 2025 |
| NCT06731153 | JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC | P2 | Triple Negative Breast Cancer (TNBC) | 40 | Dec 2024 |
| NCT05983237 | Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma | P1/P2 | Melanoma | 50 | Aug 2023 |
| NCT05624099 | Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. | P2 | Esophageal Neoplasms | 75 | Aug 2023 |
| NCT07334483 | A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC | P2 | HCC | 120 | Aug 2025 |
| NCT07530094 | STELLAR01Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | P2 | Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | 98 | Dec 2025 |
| NCT05738616 | Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) | P3 | Advanced Hepatocellular Carcinoma | 196 | May 2024 |
| NCT05854849 | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC | P3 | Nasopharyngeal Carcinoma | 244 | May 2023 |
| NCT05550558 | CAN-RESPONDCamrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer | P2 | Endometrial Cancer | 43 | Nov 2022 |
| NCT06711471 | TAS-102Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer | P2 | Gastric Cancer Adenocarcinoma Metastatic | 31 | Nov 2024 |
| NCT07312578 | Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma | P2 | Esophageal Squamous Cell Carcinoma | 48 | Nov 2025 |
| NCT05613478 | Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma | P3 | Hepatocellular Carcinoma | 130 | Jan 2023 |
| NCT05610332 | Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes | P3 | Locally Advanced Gastric Cancer | 216 | Nov 2022 |
| NCT06376721 | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | P1/P2 | Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type | 43 | Apr 2024 |
| NCT05053802 | MAGICEfficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial | P2 | Multiple Primary Lung Cancer | 146 | Mar 2021 |
| NCT05524974 | Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes | P2 | Locally Advanced Gastric Cancer | 203 | Sep 2022 |
| NCT05999149 | BCTOP-T-N01A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) | P3 | TNBC - Triple-Negative Breast Cancer | 424 | Aug 2023 |
| NCT06423937 | Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer | P2 | Colorectal Cancer | 129 | May 2024 |
| NCT06901622 | Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma | P2 | Gallbladder Cancer and Extrahepatic Cholangiocarcinoma | 50 | Nov 2024 |
| NCT07059949 | Union-mRCShort Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer | P2 | Unresectable Metastatic Rectal Cancer | 80 | Jun 2025 |
| NCT07157969 | ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | P2 | HCC - Hepatocellular Carcinoma | 300 | Feb 2025 |
| NCT06516289 | Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab | P2 | BRCA-Mutated Breast Carcinoma | 130 | Sep 2024 |
| NCT07238881 | Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment | P2 | Hepatocellulcar Carcinoma | 30 | Nov 2025 |
| NCT06435260 | Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer | P2 | Pancreatic Cancer | 30 | Aug 2024 |
| NCT06413992 | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | P2 | Endometrial Carcinoma | 117 | May 2024 |
| NCT06363825 | A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma | P2 | Advanced Hepatocellular Carcinoma | 57 | Apr 2024 |
| NCT06632405 | A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC | P2 | Breast Cancer | 60 | Apr 2025 |
| NCT06304545 | Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab | P2 | Rectal Cancer | 48 | Mar 2024 |
| NCT05738434 | Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC | P2 | Esophageal Cancer by AJCC V8 Stage | 188 | Mar 2023 |
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | P3 | Acral Melanoma | 140 | Mar 2023 |
| NCT06530082 | A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer | P1 | Breast Neoplasms | 48 | Dec 2024 |
| NCT05760378 | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | P3 | Triple-Negative Breast Cancer | 223 | Mar 2023 |
| NCT05139095 | Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia | P2 | Gestational Trophoblastic Neoplasia | 70 | Jan 2022 |
| NCT07067450 | Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma | N/A | Esophageal Squamous Cell Carcinoma (ESCC) | 98 | Jul 2025 |
| NCT06326736 | Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer | Early P1 | Pancreatic Cancer | 12 | Apr 2024 |
| NCT05841472 | Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | P2 | Non Squamous Non Small Cell Lung Cancer | 60 | Aug 2023 |
| NCT06423170 | A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs | P2 | Unresectable Gallbladder Cancer | 37 | Jun 2023 |
| NCT05772273 | PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT | N/A | Acute Myeloid Leukemia | 43 | Mar 2023 |
| NCT06241807 | Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC | P2 | IMMUNOTHERAPY | 30 | Dec 2022 |
| NCT05447702 | TNBCStudy of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | P2 | Triple Negative Breast Cancer | 35 | Nov 2022 |
| NCT05576389 | Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer | P2 | Germline BRCA-mutated HER2-negative Breast Cancer | 94 | Oct 2022 |
| NCT05512481 | Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma | P2 | Melanoma | 60 | Sep 2022 |
| NCT07320586 | Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer | P2 | Gastric Cancer | 40 | Mar 2021 |
| NCT06632522 | Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients . | P2 | Liver Cancer | 46 | Oct 2024 |
| NCT06074692 | PRIMAPARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) | P2 | Sarcoma | 86 | Jun 2023 |
| NCT05202314 | NACSOC-02Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer | N/A | Colorectal Cancer | 20 | Dec 2021 |
| NCT04299581 | Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma | P2 | Intrahepatic Cholangiocarcinoma | 25 | Jul 2020 |
| NCT06176885 | FOBECAMSEfficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | P2 | Colorectal Cancer | 36 | Dec 2023 |
| NCT06694324 | First-line Treatment of Advanced/unresectable DDLPS | P2 | Dedifferentiated Liposarcoma | 49 | Dec 2024 |
| NCT04616040 | A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer | — | Esophageal Cancer | 1,030 | Dec 2020 |
| NCT06276933 | NSCLCA Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | P4 | Lung Cancer | 104 | Feb 2024 |
| NCT06485271 | A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer | — | Gastric Cancer | 504 | Nov 2023 |
| NCT06636591 | Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer | N/A | Breast Cancer Female | 14 | Nov 2024 |
| NCT05798793 | NEOPCOSCCNeoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma | P3 | Oral Squamous Cell Carcinoma | 309 | Nov 2023 |
| NCT04481763 | A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast | P1/P2 | Triple-Negative Breast Cancer | 20 | Jul 2020 |
| NCT06546280 | A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation | P2 | Hepatocellular Carcinoma | 38 | Aug 2024 |
| NCT04342910 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | P3 | Gastric Cancer | 550 | Sep 2020 |
| NCT04830267 | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC | P2 | Nasopharyngeal Carcinoma | 39 | Mar 2021 |
| NCT05412589 | mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC | P2 | Stage III Hepatocellular Cancer (CNLC Staging) | 35 | Jun 2022 |
| NCT06010212 | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | P1/P2 | Esophageal Squamous Cell Carcinoma | 36 | Aug 2023 |
| NCT06349317 | Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT | P2 | Hepatocellular Carcinoma | 33 | Apr 2024 |
| NCT06124001 | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | P1/P2 | Primary Hepatocellular Carcinoma | 36 | Nov 2023 |
| NCT06148402 | Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer | P2 | Unresectable/Metastatic Colorectal Cancer | 30 | Nov 2023 |
| NCT06516445 | SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC | P2 | Colorectal Cancer | 33 | Jun 2023 |
| NCT05431764 | Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma | P2 | Nasopharyngeal Carcinoma | 38 | Jun 2022 |
| NCT06061276 | bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC | N/A | Liver Diseases | 40 | May 2024 |
| NCT06323382 | Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma | — | Advanced Hepatocellular Carcinoma | 240 | Jan 2021 |
| NCT06333561 | HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | — | Hepatocellular Carcinoma | 300 | Jan 2021 |
| NCT05713994 | CCGLC-001Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | — | Hepatocellular Carcinoma Non-resectable | 300 | May 2020 |
| NCT03736863 | A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | P2 | Esophageal Cancer | 147 | Dec 2019 |
| NCT06109207 | Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas | P1 | Head and Neck Squamous Cell Carcinoma | 6 | Oct 2023 |
| NCT05218889 | Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer | P1/P2 | Pancreatic Cancer | 90 | Aug 2021 |
| NCT04888429 | CAPSTONECamrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma | P2 | Sarcomatoid Carcinoma of Lung | 28 | Jul 2021 |
| NCT04318730 | Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma | P2 | Adrenocortical Carcinoma | 21 | Oct 2020 |
| NCT05717738 | CCGLC-008Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | — | Hepatocellular Carcinoma Non-resectable | 300 | Jan 2022 |
| NCT04070040 | PCNSLCamrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) | P2 | Primary Central Nervous System Lymphoma | 21 | Feb 2020 |
Camrelizumab clinical trials by indication
Hepatocellular Carcinoma (27)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07309419 | Cocktail-001 | P2/P3 | not yet recruiting | A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma |
| NCT05613478 | — | P3 | recruiting | Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma |
| NCT06546280 | — | P2 | not yet recruiting | A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation |
| NCT05320692 | — | P3 | active not recruiting | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma |
| NCT05198609 | — | P3 | active not recruiting | Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial |
| NCT06349317 | — | P2 | recruiting | Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT |
| NCT04521153 | — | P2/P3 | active not recruiting | Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma |
| NCT04559607 | — | N/A | unknown | TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma |
| + 19 more, see All trials below. | ||||
Nasopharyngeal Carcinoma (18)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07555860 | — | P2 | not yet recruiting | Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma |
| NCT06438627 | — | P3 | recruiting | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial |
| NCT04944914 | — | P3 | recruiting | Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma |
| NCT05772208 | — | P3 | recruiting | Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy |
| NCT05854849 | — | P3 | recruiting | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC |
| NCT05524168 | — | P2 | active not recruiting | SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma |
| NCT04830267 | — | P2 | recruiting | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC |
| NCT05431764 | — | P2 | recruiting | Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma |
| + 10 more, see All trials below. | ||||
Gastric Cancer (12)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05101616 | — | P1/P2 | suspended | A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer |
| NCT07320586 | — | P2 | recruiting | Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer |
| NCT06485271 | — | N/A | recruiting | A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer |
| NCT04342910 | — | P3 | recruiting | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC |
| NCT05184946 | — | P2 | unknown | Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma |
| NCT05410847 | — | P2 | unknown | Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells |
| NCT04609176 | SHR-1210 | P2 | unknown | Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma |
| NCT04631757 | GEJ | P2 | unknown | Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
| + 4 more, see All trials below. | ||||
Esophageal Squamous Cell Carcinoma (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07505186 | — | P2 | not yet recruiting | Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma |
| NCT07312578 | — | P2 | enrolling by invitation | Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma |
| NCT06654297 | — | P1 | active not recruiting | Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas |
| NCT06010212 | — | P1/P2 | not yet recruiting | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma |
| NCT04506138 | — | P1/P2 | unknown | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma |
| NCT05650216 | — | P2 | unknown | Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT） |
| NCT04984018 | — | P2 | unknown | Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade |
| NCT04866381 | — | P2 | unknown | An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody |
| + 2 more, see All trials below. | ||||
Esophageal Cancer (10)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06869226 | — | P2 | recruiting | A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer |
| NCT04616040 | — | N/A | not yet recruiting | A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer |
| NCT03736863 | — | P2 | recruiting | A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma |
| NCT05183958 | — | P2 | unknown | A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer |
| NCT04390945 | — | P2 | unknown | Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer |
| NCT04426955 | SHR-1210 | P3 | unknown | Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer |
| NCT05049681 | — | P3 | unknown | Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell |
| NCT04286958 | ESCC | P2 | unknown | A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC |
| + 2 more, see All trials below. | ||||
Cervical Cancer (8)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06288373 | — | P2/P3 | recruiting | Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC |
| NCT06288360 | — | P2 | recruiting | Neoadjuvant Immunochemotherapy in PD-L1-negative LACC |
| NCT06289062 | — | P2 | recruiting | Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer |
| NCT07466901 | — | N/A | not yet recruiting | A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer |
| NCT07167160 | — | P2 | recruiting | Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial |
| NCT04906993 | — | P3 | active not recruiting | Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer |
| NCT05151549 | — | P2 | unknown | A Study of Carilizumab Combined With Concurrent Chemoradiotherapy |
| NCT04974827 | — | P2 | unknown | A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer |
Head and Neck Squamous Cell Carcinoma (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07432087 | — | P3 | not yet recruiting | Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma |
| NCT04826679 | — | P2 | unknown | Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC |
| NCT05213884 | — | P2 | completed | The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC |
| NCT06109207 | — | P1 | recruiting | Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas |
| NCT06170697 | — | P2 | unknown | Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma |
| NCT05189184 | HNSCC | P2 | unknown | Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma |
| NCT04440917 | IMplus | P2 | unknown | Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma |
Breast Cancer (7)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04803539 | Artemis | P2/P3 | recruiting | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC |
| NCT07161791 | — | P1/P2 | not yet recruiting | Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer |
| NCT07107217 | Camella | P2 | not yet recruiting | Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer |
| NCT06632405 | — | P2 | not yet recruiting | A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC |
| NCT05097248 | — | P2 | unknown | Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy |
| NCT04303741 | — | P2 | unknown | A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC |
| NCT04805736 | — | P2 | completed | Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer |
Pancreatic Cancer (6)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06196671 | PTCA199-8 | P2 | not yet recruiting | Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer |
| NCT06435260 | — | P2 | recruiting | Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer |
| NCT06326736 | — | Early P1 | recruiting | Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer |
| NCT05218889 | — | P1/P2 | recruiting | Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer |
| NCT04420130 | — | N/A | withdrawn | A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009） |
| NCT04415385 | — | P2 | unknown | The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma |
Triple Negative Breast Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05447702 | TNBC | P2 | recruiting | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) |
| NCT04907344 | TNBC | P2/P3 | unknown | Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) |
| NCT04613674 | TNBC | P3 | completed | A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) |
| NCT04676997 | TNBC | P2 | unknown | Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) |
| NCT05134194 | — | P3 | terminated | A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer |
Locally Advanced Gastric Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05610332 | — | P3 | not yet recruiting | Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes |
| NCT05524974 | — | P2 | not yet recruiting | Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes |
| NCT06235164 | — | N/A | unknown | The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer |
| NCT05545436 | PD-1 | P2 | unknown | Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer |
| NCT04792515 | CCWSA/OAFLAG | P2 | unknown | Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer |
Non-small Cell Lung Cancer (5)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05042375 | — | P3 | unknown | A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer |
| NCT04828395 | F&C | P2 | unknown | Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer |
| NCT04793139 | — | N/A | unknown | Efficacy and Safety of Camrelizumab in Real-World Prospective Study |
| NCT04303130 | — | P2 | unknown | Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC |
| NCT04631146 | — | N/A | unknown | Efficacy and Safety of Camrelizumab in Real-World Study |
Unresectable Hepatocellular Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06485466 | — | P3 | recruiting | TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma |
| NCT06360042 | — | P2 | recruiting | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC |
| NCT04947956 | — | N/A | unknown | Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma |
| NCT05135364 | — | P2 | unknown | HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure |
Colorectal Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06423937 | — | P2 | not yet recruiting | Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer |
| NCT05202314 | NACSOC-02 | N/A | recruiting | Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer |
| NCT06176885 | FOBECAMS | P2 | recruiting | Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer |
| NCT06516445 | — | P2 | recruiting | SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC |
Advanced Hepatocellular Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05738616 | — | P3 | recruiting | Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) |
| NCT06363825 | — | P2 | recruiting | A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma |
| NCT05924997 | — | P1/P2 | unknown | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma |
| NCT06323382 | — | N/A | recruiting | Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma |
Rectal Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06229041 | — | P3 | recruiting | Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) |
| NCT04928807 | UNION | P3 | active not recruiting | Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) |
| NCT06304545 | — | P2 | not yet recruiting | Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab |
| NCT04231552 | — | P1/P2 | unknown | Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer |
Oral Squamous Cell Carcinoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05069857 | — | P2 | recruiting | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients |
| NCT05798793 | NEOPCOSCC | P3 | recruiting | Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma |
| NCT04649476 | NEOPBOSCC | P2 | completed | Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma |
| NCT05611463 | CHANCE | P2 | unknown | Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients |
Melanoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05983237 | — | P1/P2 | recruiting | Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma |
| NCT05512481 | — | P2 | recruiting | Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma |
| NCT05051865 | — | P2 | unknown | To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma |
| NCT04979585 | — | P2 | unknown | Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma |
Sarcoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06074692 | PRIMA | P2 | recruiting | PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) |
| NCT04074564 | — | Early P1 | unknown | MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma |
| NCT04447274 | — | P2 | unknown | A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS |
| NCT04126993 | — | P2 | unknown | Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma |
Triple-Negative Breast Cancer (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05760378 | — | P3 | recruiting | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. |
| NCT04481763 | — | P1/P2 | recruiting | A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast |
| NCT05670925 | — | P2 | unknown | A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC. |
| NCT04129996 | FUTURE-C-PLUS | P2 | unknown | A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS) |
Solid Tumor (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05380986 | — | N/A | unknown | Camrelizumab Combined With Apatinib Mesylate |
| NCT04832204 | — | P2 | unknown | Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases |
| NCT04346381 | — | P2 | completed | Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor |
| NCT02742935 | — | P1 | completed | A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects |
Hodgkin Lymphoma (4)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04233294 | — | P2 | unknown | Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma |
| NCT04514081 | — | P2 | unknown | The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. |
| NCT04510610 | — | P2/P3 | unknown | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma |
| NCT04239170 | SHR-1210 | P2 | unknown | Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma |
Biliary Tract Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07159217 | — | P2 | not yet recruiting | Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer |
| NCT04720131 | — | P2 | completed | Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. |
| NCT04642664 | ACABC | P2 | completed | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer |
Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07026149 | — | P2 | recruiting | Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer |
| NCT06693128 | — | P2 | active not recruiting | Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer |
| NCT04208347 | — | P2/P3 | active not recruiting | Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer |
Breast Neoplasms (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05981001 | — | P1/P2 | recruiting | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer |
| NCT06121557 | — | P1 | recruiting | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer |
| NCT06530082 | — | P1 | not yet recruiting | A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer |
Triple-negative Breast Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06533384 | — | P3 | recruiting | PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC |
| NCT05749588 | — | P2 | recruiting | FUSCC Refractory TNBC Platform Study (FUTURE2.0) |
| NCT05438706 | — | P2 | unknown | A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer |
Lung Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06276933 | NSCLC | P4 | not yet recruiting | A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) |
| NCT04782622 | — | N/A | unknown | The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy |
| NCT04201990 | CCA-MPLC | P1/P2 | unknown | Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer |
Hepatocellular Carcinoma Non-resectable (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06607107 | — | P2 | recruiting | mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria |
| NCT05713994 | CCGLC-001 | N/A | recruiting | Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma |
| NCT05717738 | CCGLC-008 | N/A | recruiting | Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma |
Advanced Solid Tumor (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04282278 | — | P2 | unknown | Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor |
| NCT05208177 | — | P2 | terminated | A Study of SHR-1802 in Patients With Advanced Solid Tumor |
| NCT03871855 | — | P1 | terminated | A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors |
Intrahepatic Cholangiocarcinoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04299581 | — | P2 | recruiting | Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma |
| NCT04454905 | — | P2 | unknown | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study |
| NCT05236699 | CCGLC-005 | P2 | completed | A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC |
Soft Tissue Sarcoma (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05189483 | — | P2 | unknown | Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. |
| NCT04606108 | — | P2 | unknown | Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma |
| NCT04910126 | — | P2 | unknown | Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma |
Advanced Gastric Cancer (3)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04195828 | — | P2 | completed | Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer |
| NCT04182724 | — | P1/P2 | unknown | Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer |
| NCT04286711 | — | P1/P2 | unknown | Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer |
HCC (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07589244 | — | P2/P3 | recruiting | A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC |
| NCT07334483 | — | P2 | recruiting | A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC |
Squamous Cell Carcinoma of Head and Neck (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07400094 | NeoCamre-HN | P2 | not yet recruiting | Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC |
| NCT05673577 | — | P2 | completed | Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients |
Locally Advanced Rectal Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07057089 | — | P2 | recruiting | Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) |
| NCT07527026 | — | P2 | recruiting | A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer |
Hepato Cellular Carcinoma (HCC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07267806 | — | P3 | recruiting | Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC |
| NCT07328009 | HCC-SIGHT | P2 | recruiting | A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma |
Cervical Cancer Metastatic (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07266350 | — | N/A | not yet recruiting | A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer |
| NCT07143292 | — | P2 | not yet recruiting | A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer |
Advanced Hepatocellular Carcinoma (HCC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07147101 | HCC-IM-1 | N/A | recruiting | Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment |
| NCT04985136 | HCC | P3 | terminated | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) |
Hepatocellular Carcinoma (HCC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07100392 | LEAF-02 | P2 | recruiting | Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab |
| NCT04639180 | HCC | P3 | active not recruiting | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation |
Triple Negative Breast Cancer (TNBC) (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06731153 | — | P2 | not yet recruiting | JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC |
| NCT05088057 | — | P2 | unknown | Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer |
Liver Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06632522 | — | P2 | not yet recruiting | Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients . |
| NCT05339581 | iPLENTY-pvtt | N/A | unknown | IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation |
Metastatic Pancreatic Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06361888 | — | P2/P3 | recruiting | A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer |
| NCT04498689 | — | P2 | unknown | Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer |
Colon Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06215677 | NITDC | N/A | recruiting | Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer |
| NCT04625803 | — | P2 | completed | Neoadjuvant Therapy for Locally Advanced Colon Cancer |
Immunotherapy (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05825443 | PANORAMA | P2 | recruiting | Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients |
| NCT04587817 | — | N/A | unknown | Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors |
Acute Myeloid Leukemia (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05772273 | — | N/A | recruiting | PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT |
| NCT04353479 | — | P2 | unknown | Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia |
Malignant Melanoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05664139 | — | P2 | unknown | Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma |
| NCT04593485 | — | P2 | unknown | Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract |
NSCLC (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05547737 | NSCLC | N/A | unknown | Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer |
| NCT05005468 | CAMFA-L | P2 | unknown | A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. |
C-staged Hepatocellular Carcinoma in BCLC Classification (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04191889 | TRIPLET | P2 | unknown | A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification |
| NCT05313282 | TRIPLET-III | P3 | unknown | A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification |
Metastatic Gastric Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04781686 | — | P2 | unknown | Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer |
| NCT05342389 | — | P2 | unknown | Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer |
Advanced Gastric Adenocarcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05583383 | — | N/A | unknown | A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab |
| NCT04174339 | SHR-1210 | N/A | unknown | PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer |
Non-Small Cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04878107 | SABRE | P2 | unknown | SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy |
| NCT04167774 | Compass-001 | P2 | unknown | A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC |
Recurrent Cervical Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05290935 | — | P2 | unknown | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial |
| NCT04188860 | — | P2 | completed | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy |
Recurrent Glioblastoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04888611 | — | P2 | unknown | Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma |
| NCT04952571 | GBM | P2 | terminated | Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM) |
Small Cell Lung Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04453930 | — | P2 | unknown | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） |
| NCT04901754 | CAMERA | P2 | unknown | Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer |
Esophageal Carcinoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05476380 | — | P2 | unknown | Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma |
| NCT03099382 | — | P3 | completed | Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer |
Non-squamous Non-small-cell Lung Cancer (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04619433 | — | P3 | terminated | A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. |
| NCT04211090 | CAP-BRAIN | P2 | unknown | Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC |
Stomach Neoplasms (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05602935 | — | P2 | active not recruiting | Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study |
| NCT04694183 | — | P2 | completed | The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer |
Gastric Cancer Stage III (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04515615 | FOCUS-02 | P2 | active not recruiting | Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) |
| NCT04152889 | — | P2 | unknown | A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer |
Classical Hodgkin Lymphoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04067037 | — | P2 | active not recruiting | Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma |
| NCT04342936 | SHR-1210 | P3 | unknown | Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma |
Osteosarcoma (2)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04294511 | — | P2 | unknown | Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma |
| NCT04351308 | MAPAC | P2 | unknown | Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma |
Rectal Cancer Patients (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07521605 | — | P2 | not yet recruiting | Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer |
Breast Cancer Triple Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07471815 | — | P2 | active not recruiting | Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy |
Unresectable Hepatocellular Carcinoma (HCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07314372 | FAD-HCC-001 | P2 | not yet recruiting | FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma |
Metastatic Colorectal Cancer (CRC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07395063 | — | P2 | not yet recruiting | A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. |
Esophageal Squamour Cell Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07191977 | — | P2 | not yet recruiting | Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma |
Hepatocellular Carcinomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07324473 | — | P2 | not yet recruiting | Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study |
Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07530094 | STELLAR01 | P2 | recruiting | Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma |
Hepatocellulcar Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07238881 | — | P2 | recruiting | Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment |
Endometrioid Endometrial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06561308 | — | P2 | recruiting | Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer |
Mixed Hepatocellular-cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07105748 | TASK-05 | P2 | recruiting | HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) |
Esophageal Squamous Cell Carcinoma (ESCC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07067450 | — | N/A | not yet recruiting | Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma |
Unresectable Metastatic Rectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07059949 | Union-mRC | P2 | not yet recruiting | Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer |
Advanced Triple Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06849492 | SHIFT-001 | P2 | not yet recruiting | HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer |
Adrenal Cortical Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06831175 | — | P2 | recruiting | Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma |
Breast Cancer Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06889688 | — | P3 | recruiting | Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer |
Potentially Resectable Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06796803 | HAIC | P2/P3 | not yet recruiting | Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) |
HCC - Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07157969 | — | P2 | recruiting | ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC |
Advanced Esophageal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06745193 | — | P2 | not yet recruiting | A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer |
Metastatic Pancreatic Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06759090 | — | P2 | not yet recruiting | Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer |
Rare Tumour (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06692491 | SPRING | P2 | not yet recruiting | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS |
Dedifferentiated Liposarcoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06694324 | — | P2 | not yet recruiting | First-line Treatment of Advanced/unresectable DDLPS |
Nasopharyngeal Cancinoma (NPC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06669611 | — | P3 | recruiting | Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma |
Breast Cancer Female (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06636591 | — | N/A | recruiting | Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer |
Gastric Cancer Adenocarcinoma Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06711471 | TAS-102 | P2 | recruiting | Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer |
Gallbladder Cancer and Extrahepatic Cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06901622 | — | P2 | enrolling by invitation | Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma |
BRCA-Mutated Breast Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06516289 | — | P2 | recruiting | Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab |
Liver Diseases (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06061276 | — | N/A | recruiting | bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC |
Endometrial Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06413992 | — | P2 | recruiting | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer |
Natural Killer/T-Cell Lymphoma, Nasal and Nasal-Type (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06376721 | — | P1/P2 | recruiting | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma |
Non-squamous Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06335355 | — | P2/P3 | not yet recruiting | A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients |
Borderline Resectable Pancreatic Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06345300 | — | P2 | unknown | NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study |
Lung Cancer, Nonsmall Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06231680 | RCCEP | P2 | unknown | Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) |
Primary Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06124001 | — | P1/P2 | not yet recruiting | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma |
Unresectable/Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06148402 | — | P2 | recruiting | Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer |
PARP Inhibitor for Esophageal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06055166 | — | P2 | unknown | A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors |
Chordoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06140732 | — | P2 | unknown | Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma |
Non Squamous Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05841472 | — | P2 | recruiting | Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer |
TNBC - Triple-Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05999149 | BCTOP-T-N01 | P3 | recruiting | A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) |
Salivary Gland Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06145308 | — | P2 | recruiting | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing |
Esophageal Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05624099 | — | P2 | recruiting | Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. |
BCLC Stage C Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06172205 | — | P3 | recruiting | Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC |
Unresectable Intrahepatic Cholangiocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05738057 | — | P2 | unknown | Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma |
Unresectable Gallbladder Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06423170 | — | P2 | recruiting | A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs |
Chemotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05821452 | — | P2 | unknown | Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma |
Macrotrabecular Massive Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05839197 | CCGLC-010 | P2 | unknown | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC |
Acral Melanoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05789043 | — | P3 | recruiting | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma |
Esophageal Cancer by AJCC V8 Stage (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05738434 | — | P2 | recruiting | Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC |
Locally Advanced Biliary Tract Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05742750 | — | P1/P2 | unknown | A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer |
Second Line Treatment of Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05669807 | — | P2 | unknown | Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer |
Metastatic Liver Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05643417 | — | P1 | unknown | Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy |
IMMUNOTHERAPY (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06241807 | — | P2 | recruiting | Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC |
Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05656131 | HRD | P2 | suspended | Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer |
Advanced Biliary Tract Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05451290 | — | P2 | active not recruiting | Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer |
Endometrial Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05550558 | CAN-RESPOND | P2 | not yet recruiting | Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer |
Breast Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05582499 | FASCINATE-N | P2 | recruiting | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy |
Ovarian Clear Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05600998 | — | N/A | unknown | A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma |
Germline BRCA-mutated HER2-negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05576389 | — | P2 | enrolling by invitation | Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer |
Peripheral T Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05559008 | — | P1/P2 | unknown | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes |
Nsclc (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05532527 | NSCLC | N/A | unknown | Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study |
Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05367687 | HCC | P2 | completed | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation |
Bladder Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05564897 | — | P2 | unknown | Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer |
Gastroesophageal Junction Adenocarcinoma (Siewert II-III) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT06163729 | — | P2 | recruiting | Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma |
Advanced Solid Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05214976 | — | P2 | unknown | A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients |
Squamous Cell Carcinoma of the Skin (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05490485 | — | P2 | unknown | Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma |
Malignant Pleural Effusion (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05330065 | — | P1/P2 | unknown | A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion |
Stage IV Gastric Cancer With Metastasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05441254 | — | P2 | unknown | Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study |
PD-1 Antibody (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05461235 | — | P2 | unknown | Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma |
Stage III Hepatocellular Cancer (CNLC Staging) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05412589 | — | P2 | recruiting | mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC |
Primary Extranodal Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05093140 | CREDIT | P2 | unknown | Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL |
Her-2 Negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05761470 | IMPARP | P2 | recruiting | Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation |
Leptomeningeal Metastasis (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05385185 | — | P2 | unknown | Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer |
Stage IV Esophagus Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05322499 | — | P2 | unknown | Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer |
Uterine Cervical Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05234905 | — | P2 | unknown | H101 Combined With Camrelizumab for Recurrent Cervical Cancer |
Cervical Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05311566 | — | P2 | unknown | PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer |
Advanced Malignant Tumors (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05198817 | — | P1 | unknown | A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients |
Colorectal Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05193292 | — | P2 | unknown | Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer |
Gestational Trophoblastic Neoplasia (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05139095 | — | P2 | recruiting | Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia |
PD-1 Inhibitor (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05222035 | — | P2 | unknown | PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure |
Advanced or Metastatic EP-NEC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05142865 | — | P2 | unknown | Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas |
Advanced NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05106335 | — | P3 | terminated | A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC |
Gastric Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05111444 | GEJ | P2 | unknown | Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma |
Efficacy and Safty of Camrelizumab Plus S-1 Maintenance After First-line Induction Chemotherapy for GC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05170542 | — | P2 | unknown | The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma. |
Non-small Cell Lung Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05472467 | IMCORT-2 | P2 | unknown | Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer |
Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05320081 | — | P2 | unknown | Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma |
PD-1 Immunotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05265793 | — | P2 | unknown | Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma |
HER2-negative Breast Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04848454 | — | P2 | unknown | Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy |
Esophageal Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05176002 | — | P1/P2 | active not recruiting | Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. |
Toxicity, Drug (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05355168 | — | P2 | completed | Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma |
Combinational Immunotherapy (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05031949 | CCGLC-003 | P1 | unknown | Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma |
HER2-positive Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05070598 | — | P2 | unknown | Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer |
Carrelizumab Plus Lenvatinib Combined With TACE (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05042336 | — | P1/P2 | unknown | The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC |
ESCC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05050760 | — | N/A | unknown | DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer |
Resectable Esophageal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05043688 | — | P3 | recruiting | Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. |
BRAF V600E-mutated /MSS Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05019534 | — | P1 | unknown | Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer |
Recurrent Nasopharyngeal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05011227 | — | P2 | unknown | Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma |
Hepatobiliary, Pancreatic and Other Gastrointestinal Carcinoma (Non-stomach, Non-esophagi) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04932187 | — | P1 | unknown | Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3) |
Lung Cancer Stage II (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04970043 | — | N/A | unknown | Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment |
Gastric Cancer, HIPEC, Anti-PD-1 Antibody Camrelizumab (SHR-1210), Chemotherapy and Surgery (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04889768 | — | N/A | unknown | HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis |
Stage IVB Cervical Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04974944 | — | P2 | unknown | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer |
Sarcomatoid Carcinoma of Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04888429 | CAPSTONE | P2 | recruiting | Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma |
Thoracic Esophageal Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04937673 | — | P2 | unknown | The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma |
Advanced Non Squamous NSCLC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04670913 | — | P2 | unknown | Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy |
Recurrent Head and Neck Squamous Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05156970 | — | P2 | completed | Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC |
Urinary Bladder Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04706598 | — | P1/P2 | active not recruiting | Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment |
HNSCC (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04861467 | — | P2 | unknown | Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma |
Advanced Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04929652 | — | P1/P2 | unknown | Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer |
Colorectal Cancer Metastatic (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04888806 | — | P2 | unknown | A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis |
Non-Small-Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04768075 | — | P3 | completed | Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC |
Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04782089 | — | N/A | unknown | Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer |
Hepatocellular Carcinoma Resectable (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04850040 | — | P2 | unknown | A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin |
Advanced Gastric Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04948125 | — | P2 | unknown | Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma |
Colorectal Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04866862 | — | P2 | unknown | Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer |
Nasal Cavity Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05114707 | — | P2 | unknown | Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses |
Small-cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04683198 | — | P2 | unknown | Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC |
Multiple Primary Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05053802 | MAGIC | P2 | recruiting | Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial |
Disease-free Survival Rate (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04782765 | — | P2 | unknown | Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma |
Locally Advanced Non-Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04749394 | — | P2 | unknown | A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy |
Pancreatic Cancer Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04674956 | — | P3 | unknown | A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer |
Esophageal Squamous Cell Carcinomas (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04741490 | — | N/A | unknown | Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery |
Advanced HER2 Negative Breast Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05085626 | — | P2 | unknown | Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer |
Extensive Stage Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05001412 | — | P1 | unknown | Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC |
Resectable Hepatocellular Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04701060 | — | P2 | completed | Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma |
Metastatic Gastric Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04510064 | — | P2 | completed | Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial |
Oligometastatic Gastrointestinal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04625894 | — | P1 | unknown | The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in Oligometastatic Gastrointestinal Cancer |
Thyroid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04612894 | — | P2 | unknown | Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer |
Non-small Cell Lung Cancer (NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT07053215 | — | N/A | completed | Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC |
Esophagus Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05637268 | — | P2 | unknown | Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma |
Glioblastoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04583020 | — | P2 | unknown | Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma |
Locally Advanced Cervical Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04884906 | — | P2 | unknown | Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer |
Hypopharyngeal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04539600 | — | P2 | unknown | Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer |
Renal Cell Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04609293 | — | N/A | unknown | Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma |
Adrenocortical Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04318730 | — | P2 | recruiting | Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma |
Early Stage Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04530227 | — | P2 | unknown | Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC |
Radioactive Iodine-refractory Differentiated Thyroid Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04560127 | — | P2 | active not recruiting | Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer |
Nasopharyngeal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04453826 | — | P3 | recruiting | Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma |
Adenocarcinoma of the Lung (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04459078 | — | P2 | unknown | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma |
Immune Checkpoint Inhibition (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04507750 | — | N/A | unknown | Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer |
Lung Cancer, Non-small Cell (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04541251 | — | P2 | unknown | Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC |
PFS (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04520035 | — | P2 | unknown | Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell |
Head and Neck Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04510818 | — | P1 | unknown | Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2) |
Advanced Cervical Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04508686 | — | P1 | unknown | Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1) |
Lung Neoplasm (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04490421 | — | P3 | unknown | Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. |
Lung Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04425135 | — | P2 | unknown | Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC |
Non Small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04379739 | — | P2 | active not recruiting | Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer |
Diffuse Large B Cell Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04476459 | — | P1/P2 | unknown | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL |
PD-L1 Positive Non-small Cell Lung Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04203485 | PD-L1 | P3 | unknown | Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) |
Head and Neck Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04405154 | — | P2 | unknown | A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer |
Hypopharyngeal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04156698 | — | P2 | unknown | Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma |
Oral Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04393506 | — | P1 | completed | Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma |
Non-small-cell Lung Cancer (NSCLC) (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04338620 | — | P2 | unknown | Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC |
Non Hodgkin Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04337606 | — | P1/P2 | unknown | Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor |
PDAC - Pancreatic Ductal Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04365049 | — | N/A | unknown | Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma |
Hepatic Metastasis of Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04202978 | — | P1/P2 | unknown | Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer |
Primary Central Nervous System Lymphoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04070040 | PCNSL | P2 | recruiting | Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) |
Locally Advanced or Metastatic Gastric Adenocarcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04572542 | — | P1/P2 | unknown | Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer |
NSCLC Stage IV (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04102982 | MWA in NSCLC | P2 | unknown | Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer |
Recurrent Platinum-resistant Ovarian Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04068974 | — | P2 | unknown | Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer |
Colorectal Cancer Recurrent (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04067986 | — | P1/P2 | unknown | Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer |
Effect of Drugs (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04044378 | — | P1/P2 | withdrawn | Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma |
Gestational Trophoblastic Disease (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04047017 | GTN | P2 | completed | Camrelizumab Combined With Apatinib for Recurrent Resistant GTN |
Advanced Colorectal Carcinoma (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT04771715 | PD-1 | N/A | unknown | Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer |
Gastrointestinal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT05225844 | — | P2 | unknown | An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal |
Metastatic Colorectal Cancer (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03912857 | SHR-1210 | P2 | unknown | Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer |
Nasopharyngeal Neoplasms (1)
| NCT | Acronym | Phase | Status | Title |
|---|---|---|---|---|
| NCT03427827 | DIPPER | P3 | unknown | PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma |
Camrelizumab pivotal trial highlights (Phase 2/3/4)
Phase-2/3/4 studies with named acronyms — the registration-grade trials most cited in label discussions and Wikipedia.
| Acronym | NCT | Phase | Status | Indication | Enrollment | PubMed |
|---|---|---|---|---|---|---|
| NSCLC | NCT06276933 | P4 | not yet recruiting | Lung Cancer | 104 | — |
| UNION | NCT04928807 | P3 | active not recruiting | Rectal Cancer | 231 | PMID 37332340 |
| BCTOP-T-N01 | NCT05999149 | P3 | recruiting | TNBC - Triple-Negative Breast Cancer | 424 | — |
| NEOPCOSCC | NCT05798793 | P3 | recruiting | Oral Squamous Cell Carcinoma | 309 | — |
| HCC | NCT04639180 | P3 | active not recruiting | Hepatocellular Carcinoma (HCC) | 687 | — |
| DIPPER | NCT03427827 | P3 | unknown | Nasopharyngeal Neoplasms | 450 | PMID 40079940 |
| TRIPLET-III | NCT05313282 | P3 | unknown | C-staged Hepatocellular Carcinoma in BCLC Classification | 140 | — |
| TNBC | NCT04613674 | P3 | completed | Triple Negative Breast Cancer | 441 | PMID 39671272 |
| SHR-1210 | NCT04426955 | P3 | unknown | Esophageal Cancer | 396 | — |
| SHR-1210 | NCT04342936 | P3 | unknown | Classical Hodgkin Lymphoma | 56 | — |
| PD-L1 | NCT04203485 | P3 | unknown | PD-L1 Positive Non-small Cell Lung Cancer | 762 | PMID 33323401 |
| HCC | NCT04985136 | P3 | terminated | Advanced Hepatocellular Carcinoma (HCC) | 1 | — |
| SPRING | NCT06692491 | P2 | not yet recruiting | Rare Tumour | 200 | — |
| FASCINATE-N | NCT05582499 | P2 | recruiting | Breast Neoplasm | 716 | PMID 38362377 |
| PANORAMA | NCT05825443 | P2 | recruiting | Immunotherapy | 57 | — |
| NeoCamre-HN | NCT07400094 | P2 | not yet recruiting | Squamous Cell Carcinoma of Head and Neck | 50 | PMID 38467604 |
| HCC-SIGHT | NCT07328009 | P2 | recruiting | Hepato Cellular Carcinoma (HCC) | 350 | — |
| FAD-HCC-001 | NCT07314372 | P2 | not yet recruiting | Unresectable Hepatocellular Carcinoma (HCC) | 86 | PMID 39300923 |
| SHIFT-001 | NCT06849492 | P2 | not yet recruiting | Advanced Triple Negative Breast Cancer | 120 | — |
| IMPARP | NCT05761470 | P2 | recruiting | Her-2 Negative Breast Cancer | 66 | — |
| TASK-05 | NCT07105748 | P2 | recruiting | Mixed Hepatocellular-cholangiocarcinoma | 45 | — |
| LEAF-02 | NCT07100392 | P2 | recruiting | Hepatocellular Carcinoma (HCC) | 141 | — |
| PTCA199-8 | NCT06196671 | P2 | not yet recruiting | Pancreatic Cancer | 30 | PMID 35399603 |
| Camella | NCT07107217 | P2 | not yet recruiting | Breast Cancer | 40 | — |
| HRD | NCT05656131 | P2 | suspended | Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer | 80 | — |
| STELLAR01 | NCT07530094 | P2 | recruiting | Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | 98 | — |
| CAN-RESPOND | NCT05550558 | P2 | not yet recruiting | Endometrial Cancer | 43 | — |
| TAS-102 | NCT06711471 | P2 | recruiting | Gastric Cancer Adenocarcinoma Metastatic | 31 | — |
| MAGIC | NCT05053802 | P2 | recruiting | Multiple Primary Lung Cancer | 146 | — |
| Union-mRC | NCT07059949 | P2 | not yet recruiting | Unresectable Metastatic Rectal Cancer | 80 | — |
| TNBC | NCT05447702 | P2 | recruiting | Triple Negative Breast Cancer | 35 | — |
| PRIMA | NCT06074692 | P2 | recruiting | Sarcoma | 86 | — |
| FOBECAMS | NCT06176885 | P2 | recruiting | Colorectal Cancer | 36 | — |
| FOCUS-02 | NCT04515615 | P2 | active not recruiting | Gastric Cancer Stage III | 52 | PMID 40656603 |
| TRIPLET | NCT04191889 | P2 | unknown | C-staged Hepatocellular Carcinoma in BCLC Classification | 47 | PMID 29471013 |
| RCCEP | NCT06231680 | P2 | unknown | Lung Cancer, Nonsmall Cell | 132 | — |
| CAPSTONE | NCT04888429 | P2 | recruiting | Sarcomatoid Carcinoma of Lung | 28 | — |
| CCGLC-010 | NCT05839197 | P2 | unknown | Macrotrabecular Massive Hepatocellular Carcinoma | 38 | — |
| HNSCC | NCT05189184 | P2 | unknown | Head and Neck Squamous Cell Carcinoma | 30 | — |
| F&C | NCT04828395 | P2 | unknown | Non-small Cell Lung Cancer | 65 | — |
| CCGLC-005 | NCT05236699 | P2 | completed | Intrahepatic Cholangiocarcinoma | 23 | PMID 41349529 |
| CREDIT | NCT05093140 | P2 | unknown | Primary Extranodal Lymphoma | 30 | — |
| SHR-1210 | NCT04609176 | P2 | unknown | Gastric Cancer | 64 | PMID 40082418 |
| PCNSL | NCT04070040 | P2 | recruiting | Primary Central Nervous System Lymphoma | 21 | — |
| HCC | NCT05367687 | P2 | completed | Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | 251 | — |
| CAMFA-L | NCT05005468 | P2 | unknown | NSCLC | 61 | — |
| C-couple | NCT04724226 | P2 | unknown | Hepatocellular Carcinoma | 34 | — |
| NEOPBOSCC | NCT04649476 | P2 | completed | Oral Squamous Cell Carcinoma | 68 | PMID 40107247 |
| GEJ | NCT05111444 | P2 | unknown | Gastric Neoplasms | 65 | — |
| CAPT | NCT04930315 | P2 | unknown | Hepatocellular Carcinoma | 78 | — |
| TNBC | NCT04676997 | P2 | unknown | Triple Negative Breast Cancer | 20 | — |
| GEJ | NCT04631757 | P2 | unknown | Gastric Cancer | 33 | — |
| IMplus | NCT04440917 | P2 | unknown | Head and Neck Squamous Cell Carcinoma | 32 | — |
| IMCORT-2 | NCT05472467 | P2 | unknown | Non-small Cell Lung Cancer Metastatic | 35 | — |
| SABRE | NCT04878107 | P2 | unknown | Non-Small Cell Lung Cancer | 88 | — |
| PD-1 | NCT05545436 | P2 | unknown | Locally Advanced Gastric Cancer | 34 | — |
| CHANCE | NCT05611463 | P2 | unknown | Oral Squamous Cell Carcinoma | 25 | — |
| CAMERA | NCT04901754 | P2 | unknown | Small Cell Lung Carcinoma | 38 | — |
| ESCC | NCT04767295 | P2 | unknown | Esophageal Squamous Cell Carcinoma | 28 | — |
| ESCC | NCT04286958 | P2 | unknown | Esophageal Cancer | 40 | PMID 42031221 |
| GBM | NCT04952571 | P2 | terminated | Recurrent Glioblastoma | 3 | — |
| CCWSA/OAFLAG | NCT04792515 | P2 | unknown | Locally Advanced Gastric Cancer | 67 | — |
| MAPAC | NCT04351308 | P2 | unknown | Osteosarcoma | 60 | — |
| SHR-1210 | NCT04239170 | P2 | unknown | Hodgkin Lymphoma | 84 | PMID 38454451 |
| CAP-BRAIN | NCT04211090 | P2 | unknown | Non-squamous Non-small-cell Lung Cancer | 45 | PMID 38169917 |
| Compass-001 | NCT04167774 | P2 | unknown | Non-Small Cell Lung Cancer | 62 | — |
| FUTURE-C-PLUS | NCT04129996 | P2 | unknown | Triple-Negative Breast Cancer | 46 | PMID 35337339 |
| MWA in NSCLC | NCT04102982 | P2 | unknown | NSCLC Stage IV | 200 | — |
| GTN | NCT04047017 | P2 | completed | Gestational Trophoblastic Disease | 20 | PMID 34624252 |
| ACABC | NCT04642664 | P2 | completed | Biliary Tract Cancer | 22 | PMID 33087333 |
| SHR-1210 | NCT03912857 | P2 | unknown | Metastatic Colorectal Cancer | 50 | PMID 26755520 |
Terminated and withdrawn Camrelizumab trials (11)
Studies that ended before completion. Reasons are filed in each trial's ClinicalTrials.gov entry.
- NCT05656131suspendedFluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer
- NCT05101616suspendedA Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer
- NCT04619433terminatedA Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC.
- NCT05208177terminatedA Study of SHR-1802 in Patients With Advanced Solid Tumor
- NCT04420130withdrawnA Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009）
- NCT04952571terminatedCombined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM)
- NCT05134194terminatedA Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer
- NCT04044378withdrawnFamitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
- NCT05106335terminatedA Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC
- NCT04985136terminatedA Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC)
- NCT03871855terminatedA Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors
All Camrelizumab trials (410)
Sorted by most recent activity (completion → start → posted date). Each row links to the trial detail page on Hipa.ai.
| NCT ID | Acronym | Title | Phase | Status | Enrollment | Sponsor | Started |
|---|---|---|---|---|---|---|---|
| NCT05981001 | Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | P1/P2 | recruiting | 170 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Aug 2023 | |
| NCT07521605 | Short-Course Radiotherapy, Nal-IRI, Capecitabine, and Camrelizumab for Locally Advanced MSS Rectal Cancer | P2 | not yet recruiting | 44 | Guangdong Provincial People's Hospital | May 2026 | |
| NCT07505186 | Camrelizumab, Chemotherapy and Ivarmacitinib in Patients With Resectable Esophageal Squamous Cell Carcinoma | P2 | not yet recruiting | 45 | Second Affiliated Hospital, School of Medicine, Zhejiang University | May 2026 | |
| NCT07432087 | Camrelizumab Combined With EGFR Monoclonal Antibody or Chemotherapy for Perioperative Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma | P3 | not yet recruiting | 246 | Yue He, MD | Feb 2026 | |
| NCT04803539 | Artemis | A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBC | P2/P3 | recruiting | 260 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Apr 2021 |
| NCT07267806 | Camrelizumab and Apatinib With or Without FOLFOX Chemotherapy for Advanced HCC | P3 | recruiting | 326 | Linhui Peng | Oct 2025 | |
| NCT06831175 | Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical Carcinoma | P2 | recruiting | 28 | West China Hospital | Mar 2025 | |
| NCT06121557 | Phase I Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer | P1 | recruiting | 24 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Nov 2023 | |
| NCT06561308 | Clinical Efficacy Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Advanced Endometrial Cancer | P2 | recruiting | 39 | Women's Hospital School Of Medicine Zhejiang University | Sep 2025 | |
| NCT06288373 | Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC | P2/P3 | recruiting | 440 | Tongji Hospital | Apr 2024 | |
| NCT06533384 | PARPi or Capecitabine Combined With PD-1 Inhibitors as Adjuvant Therapy in High-risk TNBC | P3 | recruiting | 310 | Guangdong Provincial People's Hospital | Aug 2024 | |
| NCT05043688 | Camrelizumab Plus Neoadjuvant Chemotherapy or Chemoradiotherapy Versus Chemoradiotherapy in Resectable ESCC. | P3 | recruiting | 426 | Zhigang Li | Sep 2021 | |
| NCT07266350 | A Non-interventional Registration Study of Monotherapy or Combination Regimens Based on Camrelizumab or Famitinib for the Treatment of Cervical Cancer | — | not yet recruiting | 1,300 | Qi Zhou | Dec 2025 | |
| NCT06288360 | Neoadjuvant Immunochemotherapy in PD-L1-negative LACC | P2 | recruiting | 40 | Tongji Hospital | Sep 2024 | |
| NCT07057089 | Involved-field Radiotherapy-TNT Combined With PD-1 Inhibitor for pMMR Locally Advanced Rectal Cancer (Neo-Field I) | P2 | recruiting | 90 | Hebei Medical University Fourth Hospital | Jul 2025 | |
| NCT06289062 | Neoadjuvant Chemotherapy Plus Camrelizumab for FIGO Stage IB1 Cervical Cancer | P2 | recruiting | 40 | Tongji Hospital | May 2024 | |
| NCT06335355 | A Phase II/III Study of Adebrelimab in Combination With SHR-8068 and Chemotherapy in Advanced or Metastatic NSCLC Patients | P2/P3 | not yet recruiting | 401 | Shanghai Shengdi Pharmaceutical Co., Ltd | Mar 2024 | |
| NCT07466901 | A Single-arm, Multicenter, Phase II Clinical Study of Camrelizumab Combined With Famitinib in Adjuvant Therapy After Radical Resection of Cervical Cancer | N/A | not yet recruiting | 30 | Jin LI | Apr 2026 | |
| NCT07309419 | Cocktail-001 | A Phase III Randomized Study of TACE Plus an Oral Triple-Agent Cocktail Versus TACE Plus First-Line Targeted Immunotherapy in Unresectable Hepatocellular Carcinoma | P2/P3 | not yet recruiting | 222 | Shanghai Zhongshan Hospital | Dec 2025 |
| NCT07026149 | Perioperative Treatment of Combined Radiotherapy With SOX, Apatinib and Camrelizumab for Oesophagogastric Cancer | P2 | recruiting | 30 | Ruijin Hospital | Jun 2025 | |
| NCT06796803 | HAIC | Camrelizumab Combined with Rivoceranib and Hepatic Arterial Infusion Chemotherapy (HAIC) As Conversion Therapy for Potentially Resectable Hepatocellular Carcinoma(HCC) | P2/P3 | not yet recruiting | 398 | Shanghai Zhongshan Hospital | Feb 2025 |
| NCT06215677 | NITDC | Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer | N/A | recruiting | 18 | Peking Union Medical College Hospital | Jan 2024 |
| NCT07555860 | Becotatug Vedotin Plus PD-1 Monoclonal Antibody and Radiotherapy for Unresectable Locally Recurrent Nasopharyngeal Carcinoma | P2 | not yet recruiting | 28 | Sun Yat-sen University | Apr 2026 | |
| NCT07191977 | Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinoma | P2 | not yet recruiting | 41 | West China Hospital | Jan 2026 | |
| NCT06869226 | A Multicenter Phase II Clinical Study of Neoadjuvant Use of Camrelizumab in Combination With Chemotherapy for Organ Preservation in Esophageal Cancer | P2 | recruiting | 283 | Peking University Cancer Hospital & Institute | Apr 2025 | |
| NCT07167160 | Chemo-immunotherapy for Cervical Cancer Stage IIICp Trial | P2 | recruiting | 59 | Women's Hospital School Of Medicine Zhejiang University | Mar 2025 | |
| NCT06692491 | SPRING | Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS | P2 | not yet recruiting | 200 | Peking University Shenzhen Hospital | Jan 2025 |
| NCT06669611 | Nab-TPC vs GP Combined With Camrelizumab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma | P3 | recruiting | 242 | Sun Yat-sen University | Nov 2024 | |
| NCT06229041 | Total Neoadjuvant Treatment ±Immunotherapy for High Risk Locally Advanced Rectal Cancer (TNTi) | P3 | recruiting | 472 | Peking University Cancer Hospital & Institute | Mar 2023 | |
| NCT05582499 | FASCINATE-N | Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant Therapy | P2 | recruiting | 716 | Fudan University | Nov 2022 |
| NCT06172205 | Infusional FOLFOX Plus Camrelizumab and Apatinib vs HAIC-FOLFOX Plus Camrelizumab and Apatinib for Advanced HCC | P3 | recruiting | 262 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Jul 2023 | |
| NCT07589244 | A Study of VRT106, Combined With Camrelizumab, and Apatinib for Advanced HCC | P2/P3 | recruiting | 66 | Guangzhou Virotech Pharmaceutical Co., Ltd. | May 2026 | |
| NCT06889688 | Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast Cancer | P3 | recruiting | 246 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Feb 2025 | |
| NCT06438627 | Efficacy and Safety of TPC+Apatinib+Camrelizumab vs GP+ Camrelizumab for High-Risk Nasopharyngeal Carcinoma: A Phase 3 Trial | P3 | recruiting | 164 | XIANG YANQUN | May 2024 | |
| NCT05825443 | PANORAMA | Adjuvant Chemotherapy Combined With Camrelizumab for ⅡA -ⅢA NSCLC Patients | P2 | recruiting | 57 | Nanfang Hospital, Southern Medical University | Apr 2023 |
| NCT07471815 | Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy | P2 | active not recruiting | 30 | Harbin Medical University | Mar 2026 | |
| NCT07400094 | NeoCamre-HN | Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC | P2 | not yet recruiting | 50 | National Medical Research Radiological Centre of the Ministry of Health of Russia | Feb 2026 |
| NCT07527026 | A Single-arm Phase II Clinical Study of Camrelizumab Combined With Long-course Chemoradiotherapy for Total Neoadjuvant Therapy in Locally Advanced Low pMMR/MSS Rectal Cancer | P2 | recruiting | 44 | Chinese PLA General Hospital | Feb 2026 | |
| NCT07395063 | A Clinical Study on the Treatment of Metastatic Colorectal Cancer at the Second-line or Beyond. | P2 | not yet recruiting | 68 | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | Feb 2026 | |
| NCT07328009 | HCC-SIGHT | A Platform Trial for Personalized and Adaptive Therapies in Hepatocellular Carcinoma | P2 | recruiting | 350 | Fudan University | Jan 2026 |
| NCT07324473 | Ivarmacitinib Combined With Camrelizumab and Apatinib for Unresectable Advanced Hepatocellular Carcinoma With Acquired Resistance to Immune Checkpoint Therapy: A Single-Arm Exploratory Clinical Study | P2 | not yet recruiting | 65 | First Affiliated Hospital of Chongqing Medical University | Jan 2026 | |
| NCT07314372 | FAD-HCC-001 | FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular Carcinoma | P2 | not yet recruiting | 86 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Feb 2026 |
| NCT06849492 | SHIFT-001 | HIM Typing Guides the Treatment of Advanced First-Line Triple-Negative Breast Cancer | P2 | not yet recruiting | 120 | Fudan University | Apr 2025 |
| NCT05749588 | FUSCC Refractory TNBC Platform Study (FUTURE2.0) | P2 | recruiting | 120 | Fudan University | Mar 2023 | |
| NCT05761470 | IMPARP | Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation | P2 | recruiting | 66 | Ying Lin | May 2022 |
| NCT04453826 | Concurrent and Adjuvant PD1 Treatment Combined With Chemo-radiotherapy for High-risk Nasopharyngeal Carcinoma | P3 | recruiting | 388 | Sun Yat-sen University | Sep 2020 | |
| NCT07147101 | HCC-IM-1 | Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune Microenvironment | — | recruiting | 150 | Fudan University | Sep 2025 |
| NCT07105748 | TASK-05 | HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA) | P2 | recruiting | 45 | Fudan University | Aug 2025 |
| NCT07100392 | LEAF-02 | Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab | P2 | recruiting | 141 | Fudan University | Aug 2025 |
| NCT06145308 | Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing | P2 | recruiting | 39 | Peking Union Medical College | Aug 2023 | |
| NCT07143292 | A Prospective, Randomized, Parallel Trial of Famitinib Malate at Different Doses Combined With Camrelizumab for the Treatment of Recurrent and Metastatic Cervical Cancer | P2 | not yet recruiting | 120 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Nov 2025 | |
| NCT06485466 | TACE Plus Camrelizumab and Apatinib for Unresectable Hepatocellular Carcinoma | P3 | recruiting | 101 | Guohui Xu | Aug 2024 | |
| NCT05069857 | Neoadjuvant Personalized Anti-PD-1 and Anti-VEGFR Therapy in OSCC Patients | P2 | recruiting | 46 | Shanghai Jiao Tong University School of Medicine | Sep 2021 | |
| NCT06759090 | Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic Cancer | P2 | not yet recruiting | 43 | Zhejiang University | Jan 2025 | |
| NCT04944914 | Camrelizumab Plus Stereotactic Body Radiotherapy vs Camrelizumab Alone For Oligometastatic Nasopharyngeal Carcinoma | P3 | recruiting | 188 | Sun Yat-sen University | Jun 2021 | |
| NCT07159217 | Disitamab Vedotin Plus Lenvatinib and PD-1 Inhibitors for Treating HER2-positive Advanced Biliary Tract Cancer | P2 | not yet recruiting | 65 | Peking Union Medical College Hospital | Aug 2025 | |
| NCT06361888 | A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer | P2/P3 | recruiting | 502 | Hutchmed | May 2024 | |
| NCT06163729 | Camrelizumab Combined With Chemotherapy and Radiotherapy Perioperative Treatment of Esophageal Gastric Junction Adenocarcinoma | P2 | recruiting | 68 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Aug 2022 | |
| NCT06360042 | Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC | P2 | recruiting | 111 | Peking University Cancer Hospital & Institute | Jan 2024 | |
| NCT04928807 | UNION | Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION) | P3 | active not recruiting | 231 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Jul 2021 |
| NCT06745193 | A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal Cancer | P2 | not yet recruiting | 63 | Peking University | Feb 2025 | |
| NCT06607107 | mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria | P2 | recruiting | 29 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Feb 2024 | |
| NCT06196671 | PTCA199-8 | Oncolytic Virus Plus PD-1 Inhibitor to Patients With Advanced Pancreatic Cancer | P2 | not yet recruiting | 30 | Fudan University | Dec 2026 |
| NCT05772208 | Intensified Treatments for Patients With Locally Advanced Nasopharyngeal Carcinoma With Detectable EBV DNA After One Cycle GP Regime Neoadjuvant Chemotherapy | P3 | recruiting | 459 | Fudan University | Jan 2022 | |
| NCT07161791 | Camrelizumab, Pirfenidone, and Chemotherapy in the Treatment of Advanced Triple-Negative Breast Cancer | P1/P2 | not yet recruiting | 12 | Harbin Medical University | Sep 2025 | |
| NCT07107217 | Camella | Camrelizumab in Combination With Chemotherapy as Neoadjuvant Treatment in Patients With Early or Locally Advanced Triple-negative Breast Cancer | P2 | not yet recruiting | 40 | Blokhin's Russian Cancer Research Center | Aug 2025 |
| NCT06731153 | JAK1 Inhibitor Ivarmacitinib Reversing Immunotherapy Resistance in TNBC | P2 | not yet recruiting | 40 | Fudan University | Dec 2024 | |
| NCT06693128 | Camrelizumab Combined With or Without Apatinib and SOX of Neoadjuvant Treatment for Gastric Cancer | P2 | active not recruiting | 80 | Ruijin Hospital | Nov 2024 | |
| NCT05983237 | Fluzoparib in Combination With Camrelizumab and Temozolomide in Advanced Melanoma | P1/P2 | recruiting | 50 | Jun Guo | Aug 2023 | |
| NCT05624099 | Camrelizumab Combined With Chemoradiotherapy in Advanced Esophageal Cancer. | P2 | recruiting | 75 | Fujian Cancer Hospital | Aug 2023 | |
| NCT05656131 | HRD | Fluzoparib in Combination With or Without Camrelizumab for Homologous Recombinant Deficiency (HRD) HER2 Negative Advanced Breast Cancer | P2 | suspended | 80 | wang shusen | Nov 2022 |
| NCT04208347 | Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric Cancer | P2/P3 | active not recruiting | 580 | Ruijin Hospital | Dec 2019 | |
| NCT07334483 | A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCC | P2 | recruiting | 120 | GrandPharma (China) Co., Ltd. | Aug 2025 | |
| NCT07530094 | STELLAR01 | Short-Course Definitive Chemoradiotherapy Combined With Adjuvant or Concurrent Plus Adjuvant Camrelizumab for Locally Advanced Unresectable Esophageal Squamous Cell Carcinoma | P2 | recruiting | 98 | Ning Jiang, M.D./Ph.D. | Dec 2025 |
| NCT05738616 | Lenvatinib Combined With TACE and Camrelizumab in Conversion Resection for Advanced Hepatocellular Carcinoma (LEN-TAC Study) | P3 | recruiting | 196 | Wen Tianfu | May 2024 | |
| NCT05854849 | Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPC | P3 | recruiting | 244 | Sun Yat-sen University | May 2023 | |
| NCT05550558 | CAN-RESPOND | Camrelizumab Plus Anlotinib in Patients With Recurrent Sporadic MMRd Endometrial Cancer | P2 | not yet recruiting | 43 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Nov 2022 |
| NCT06711471 | TAS-102 | Trifluridine/tipiracil (TAS-102), Bevacizumab, and Camrelizumab As Third-line or Later-line Therapy of Gastric Cancer | P2 | recruiting | 31 | LIN YANG | Nov 2024 |
| NCT07312578 | Nimotuzumab,Camrelizumab, and Neoadjuvant Chemotherapy（nCT） in the Treatment of Esophageal Squamous Cell Carcinoma | P2 | enrolling by invitation | 48 | Peking University | Nov 2025 | |
| NCT05613478 | Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma | P3 | recruiting | 130 | The First Affiliated Hospital with Nanjing Medical University | Jan 2023 | |
| NCT05610332 | Clinical Efficacy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Immunotypes | P3 | not yet recruiting | 216 | Fujian Medical University | Nov 2022 | |
| NCT06376721 | Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma | P1/P2 | recruiting | 43 | Beijing Tongren Hospital | Apr 2024 | |
| NCT05053802 | MAGIC | Efficiency and Safety of Microwave Ablation Plus Immune Checkpoint Inhibitor for Patients With Multiple Primary Lung Cancer: A Open, Multi-center, Phase II Clinical Trial | P2 | recruiting | 146 | Shanghai Pulmonary Hospital, Shanghai, China | Mar 2021 |
| NCT05524974 | Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different Genotypes | P2 | not yet recruiting | 203 | Fujian Medical University | Sep 2022 | |
| NCT05999149 | BCTOP-T-N01 | A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01) | P3 | recruiting | 424 | Fudan University | Aug 2023 |
| NCT06423937 | Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer | P2 | not yet recruiting | 129 | Fudan University | May 2024 | |
| NCT06901622 | Camrelizumab and Chemotherapy With or Without Anlotinib as First-line Treatment for Advanced Gallbladder Cancer and Extrahepatic Cholangiocarcinoma | P2 | enrolling by invitation | 50 | The First Affiliated Hospital of Zhengzhou University | Nov 2024 | |
| NCT07059949 | Union-mRC | Short Course Radiotherapy Followed by CAPOX and Carrilizumab and Bevacizumab or Cetuximab for the Initial Treatment of Unresectable Metastatic Rectal Cancer | P2 | not yet recruiting | 80 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Jun 2025 |
| NCT07157969 | ICIs and Anti-VEGF Antibody/TKIs With or Without Interventional Therapy for Advanced HCC | P2 | recruiting | 300 | Peking Union Medical College Hospital | Feb 2025 | |
| NCT06516289 | Neoadjuvant Treatment of gBRCA-Mutated HER2-Negative Breast Cancer With HRS-1167 and Famitinib ± Camrelizumab | P2 | recruiting | 130 | Fudan University | Sep 2024 | |
| NCT07238881 | Dalpiciclib Plus Camrelizumab for HCC Patients Who Have Previously Received ICI Treatment | P2 | recruiting | 30 | Sun Yat-sen University | Nov 2025 | |
| NCT06435260 | Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer | P2 | recruiting | 30 | Hebei Medical University Fourth Hospital | Aug 2024 | |
| NCT06413992 | Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer | P2 | recruiting | 117 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | May 2024 | |
| NCT04906993 | Camrelizumab Combined With Famitinib Malate for Treatment of Recurrent/Metastatic Cervical Cancer | P3 | active not recruiting | 443 | Jiangsu HengRui Medicine Co., Ltd. | Jul 2021 | |
| NCT06363825 | A Study of TAE+HAIC Combined With Camrelizumab and Apatinib in the Treatment of Advanced Hepatocellular Carcinoma | P2 | recruiting | 57 | Fujian Medical University | Apr 2024 | |
| NCT06632405 | A Trial of Camrelizumab Plus Nab-paclitaxel and Levocetirizine in Metastatic or Recurrent TNBC | P2 | not yet recruiting | 60 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Apr 2025 | |
| NCT06304545 | Treatment of Rectal Cancer With Long-term Concurrent Chemoradiotherapy Combined With Camrelizumab | P2 | not yet recruiting | 48 | Harbin Medical University | Mar 2024 | |
| NCT05738434 | Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC | P2 | recruiting | 188 | The First Affiliated Hospital of Zhengzhou University | Mar 2023 | |
| NCT05789043 | Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral Melanoma | P3 | recruiting | 140 | Peking University Cancer Hospital & Institute | Mar 2023 | |
| NCT06654297 | Neoadjuvant Camrelizumab With Palbociclib for Resectable Esophageal Squamous Cell Carcinomas | P1 | active not recruiting | 6 | West China Hospital | Oct 2024 | |
| NCT06530082 | A Single Arm Clinical Study of Dendritic Cell Vaccine Loaded With Circular RNA Encoding Cryptic Peptide for Patients With HER2-negative Advanced Breast Cancer | P1 | not yet recruiting | 48 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Dec 2024 | |
| NCT05760378 | Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC. | P3 | recruiting | 223 | Fudan University | Mar 2023 | |
| NCT05101616 | A Pilot Study of Neoadjuvant Chemotherapy With or Without Camrelizumab for Locally Advanced Gastric Cancer | P1/P2 | suspended | 100 | Shanghai Minimally Invasive Surgery Center | Jul 2022 | |
| NCT05139095 | Camrelizumab Plus Apatinib in Patients With High-risk Gestational Trophoblastic Neoplasia | P2 | recruiting | 70 | Peking Union Medical College Hospital | Jan 2022 | |
| NCT07067450 | Adjuvant Immunotherapy for Esophageal Squamous Cell Carcinoma | N/A | not yet recruiting | 98 | Sichuan University | Jul 2025 | |
| NCT06326736 | Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer | Early P1 | recruiting | 12 | Jinling Hospital, China | Apr 2024 | |
| NCT05841472 | Anti-PD-1 Antibody Therapies of Camrelizumab in Combination With Pemetrexed and Carboplatin as First-line Treatment in Patients With Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer | P2 | recruiting | 60 | CrystalGenomics, Inc. | Aug 2023 | |
| NCT06423170 | A Single-arm Phase II Clinical Study of the Efficacy and Safety of Camrelizumab Combined With GEMOX for Unresectable GBCs | P2 | recruiting | 37 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Jun 2023 | |
| NCT05772273 | PD-1 Inhibitor, Azacitidine and Low-dose DLI in AML Relapse After Allo-HSCT | N/A | recruiting | 43 | The First Affiliated Hospital of Soochow University | Mar 2023 | |
| NCT06241807 | Neoadjuvant Camrelizumab Combined With Chemotherapy for Resectable Stage IIIA-IIIB NSCLC | P2 | recruiting | 30 | Shandong Cancer Hospital and Institute | Dec 2022 | |
| NCT05524168 | SBRT Combined With PD-1 Antibody and Chemotherapy in Oligometastatic Nasopharyngeal Carcinoma | P2 | active not recruiting | 41 | Sun Yat-sen University | Nov 2022 | |
| NCT05447702 | TNBC | Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | P2 | recruiting | 35 | West China Hospital | Nov 2022 |
| NCT05576389 | Neoadjuvant Fluzoparib Combined With Camrelizumab in Germline BRCA-mutated HER2-negative Breast Cancer | P2 | enrolling by invitation | 94 | Peking University People's Hospital | Oct 2022 | |
| NCT05512481 | Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma | P2 | recruiting | 60 | Peking University Cancer Hospital & Institute | Sep 2022 | |
| NCT07320586 | Carilizumab and Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer | P2 | recruiting | 40 | Shandong Tumor Hospital | Mar 2021 | |
| NCT04067037 | Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma | P2 | active not recruiting | 60 | Henan Cancer Hospital | Aug 2019 | |
| NCT06632522 | Clinical Study of Radiotherapy Combined With Camrelizumab and Apatinib in the Treatment of Liver Cancer Patients . | P2 | not yet recruiting | 46 | Beijing Tsinghua Chang Gung Hospital | Oct 2024 | |
| NCT06074692 | PRIMA | PARP Inhibition, Stereotactic Body Radiotherapy and Immunotherapy for Metastatic or Advanced Sarcoma (PRIMA) | P2 | recruiting | 86 | Ruijin Hospital | Jun 2023 |
| NCT05202314 | NACSOC-02 | Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer | N/A | recruiting | 20 | Beijing Chao Yang Hospital | Dec 2021 |
| NCT05602935 | Efficacy and Safety of SOX Regimen Combined With Camrelizumab as Neoadjuvant Treatment in Locally Advanced Gastric Cancer: a Phase II, Single-arm Study | P2 | active not recruiting | 29 | The Second Affiliated Hospital of Fujian Medical University | Sep 2020 | |
| NCT04379739 | Neoadjuvant PD-1 Antibody Plus Apatinib or Chemotherapy for Non-small Cell Lung Cancer | P2 | active not recruiting | 89 | Shanghai Pulmonary Hospital, Shanghai, China | Jul 2020 | |
| NCT04299581 | Cryoablation Combined with Anti-PD-1 Antibody in Patients with Advanced Intrahepatic Cholangiocarcinoma | P2 | recruiting | 25 | Fudan University | Jul 2020 | |
| NCT06176885 | FOBECAMS | Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer | P2 | recruiting | 36 | yue junhan | Dec 2023 |
| NCT05451290 | Camrelizumab Plus Apatinib in Combination With GEMOX (Gemcitabine and Oxaliplatin ) in Patients With Locally Advanced Biliary Tract Cancer | P2 | active not recruiting | 30 | First Affiliated Hospital of Zhejiang University | Nov 2022 | |
| NCT06694324 | First-line Treatment of Advanced/unresectable DDLPS | P2 | not yet recruiting | 49 | Fudan University | Dec 2024 | |
| NCT04616040 | A Real-world Study Evaluating the Usage of Camrelizumab in Chinese Patients With Advanced Esophageal Cancer | — | not yet recruiting | 1,030 | Peking University | Dec 2020 | |
| NCT05176002 | Camrelizumab in Combination With Radiotherapy for Neoadjuvant Esophageal Carcinoma. | P1/P2 | active not recruiting | 25 | Fujian Medical University Union Hospital | Nov 2021 | |
| NCT06276933 | NSCLC | A Study of Camrelizumab Combined With Chemotherapy ± Thalidomide in First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) | P4 | not yet recruiting | 104 | Tongji University | Feb 2024 |
| NCT06485271 | A Real-world Study of Camrelizumab Alone or in Combination With Apatinib/Chemotherapy for Advanced Gastric Cancer | — | recruiting | 504 | Changzhi People's Hospital Affiliated to Changzhi Medical College | Nov 2023 | |
| NCT06636591 | Pilot Study of Neoadjuvant Chemotherapy Combined With Immunotherapy and Multimodal Thermal Therapy for HER2-negative Breast Cancer | N/A | recruiting | 14 | Fudan University | Nov 2024 | |
| NCT05798793 | NEOPCOSCC | Neoadjuvant Anti-PD-1 Immunotherapy With Chemotherapy in Resectable Locally Advanced Oral Squamous Cell Carcinoma | P3 | recruiting | 309 | Hospital of Stomatology, Wuhan University | Nov 2023 |
| NCT04481763 | A Study of the Efficacy and Safety of Camrelizumab Plus Radiotherapy for Patients With Early Triple-Negative Breast | P1/P2 | recruiting | 20 | Jiangxi Provincial Cancer Hospital | Jul 2020 | |
| NCT06546280 | A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or Ablation | P2 | not yet recruiting | 38 | Zhujiang Hospital | Aug 2024 | |
| NCT04342910 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | P3 | recruiting | 550 | Jiangsu HengRui Medicine Co., Ltd. | Sep 2020 | |
| NCT04830267 | The Efficacy of Camrelizumab Plus Stereotactic Body Radiotherapy in R/M NPC | P2 | recruiting | 39 | Chongqing University Cancer Hospital | Mar 2021 | |
| NCT05412589 | mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCC | P2 | recruiting | 35 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Jun 2022 | |
| NCT04639180 | HCC | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | P3 | active not recruiting | 687 | Jiangsu HengRui Medicine Co., Ltd. | Apr 2021 |
| NCT05320692 | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | P3 | active not recruiting | 423 | Jiangsu HengRui Medicine Co., Ltd. | Aug 2022 | |
| NCT06010212 | Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma | P1/P2 | not yet recruiting | 36 | The First Affiliated Hospital with Nanjing Medical University | Aug 2023 | |
| NCT05198609 | Camrelizumab, Apatinib Plus HAIC Versus Camrelizumab and Apatinib for HCC With Portal Vein Invasion: a Randomized Trial | P3 | active not recruiting | 214 | Sun Yat-sen University | Jan 2022 | |
| NCT06349317 | Neoadjuvant IMRT Combined With Camrelizumab and Apatinib for Resectable HCC With PVTT | P2 | recruiting | 33 | Yongyi Zeng | Apr 2024 | |
| NCT06124001 | Clinical Study of VG161 Combined With Camrelizumab in Patients With Advanced Primary Hepatocellular Carcinoma | P1/P2 | not yet recruiting | 36 | CNBG-Virogin Biotech (Shanghai) Ltd. | Nov 2023 | |
| NCT06148402 | Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer | P2 | recruiting | 30 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Nov 2023 | |
| NCT06516445 | SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC | P2 | recruiting | 33 | Huazhong University of Science and Technology | Jun 2023 | |
| NCT05431764 | Whole-target Consolidation Therapy Under Systemic Therapy for Oligometastatic Nasopharyngeal Carcinoma | P2 | recruiting | 38 | Sun Yat-sen University | Jun 2022 | |
| NCT05924997 | Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma | P1/P2 | unknown | 52 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Jul 2023 | |
| NCT06055166 | A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors | P2 | unknown | 120 | Chongqing University Cancer Hospital | Nov 2023 | |
| NCT05821452 | Immunotherapy Plus Chemotherapy vs. Chemoradiotherapy for Thoracic Squamous Esophageal Carcinoma | P2 | unknown | 40 | Fujian Medical University Union Hospital | May 2023 | |
| NCT04768075 | Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLC | P3 | completed | 60 | Guangdong Association of Clinical Trials | May 2021 | |
| NCT05097209 | Camrelizumab for the Treatment of Locally Advanced Nasopharyngeal Carcinoma | P2 | unknown | 200 | Wei Jiang | Apr 2022 | |
| NCT04337606 | Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor | P1/P2 | unknown | 100 | Chinese PLA General Hospital | Apr 2020 | |
| NCT04826679 | Neoadjuvant Camrelizumab in Combination With Cisplatin and Nab-paclitaxel in Resectable HNSCC | P2 | unknown | 53 | Sun Yat-sen University | Apr 2021 | |
| NCT04515615 | FOCUS-02 | Adjuvant Chemotherapy in Combination With Camrelizumab for Stage III Gastric Cancer (FOCUS-02) | P2 | active not recruiting | 52 | Yu jiren | Sep 2020 |
| NCT05311566 | PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer | P2 | unknown | 92 | Lei Li | Mar 2022 | |
| NCT05738057 | Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma | P2 | unknown | 22 | Hua Li | Jun 2023 | |
| NCT04521153 | Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma | P2/P3 | active not recruiting | 294 | Shanghai Zhongshan Hospital | Mar 2021 | |
| NCT04233294 | Addition of Chidamide to the Combination Treatment of Decitabine Plus Camrelizumab in Combination Treatment Resistant/Relapsed Patients With Classical Hodgkin Lymphoma | P2 | unknown | 100 | Chinese PLA General Hospital | Feb 2020 | |
| NCT03427827 | DIPPER | PD-1 Antibody Versus Best Supportive Care After Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma | P3 | unknown | 450 | Sun Yat-sen University | Jul 2018 |
| NCT05213884 | The Efficacy of Induction and Adjuvant Camrelizumab Combined With Chemoradiation for LA-HNSCC | P2 | completed | 39 | Chongqing University Cancer Hospital | Jan 2022 | |
| NCT06140732 | Apatinib Combined With Camrelizumab in Treating Participants With Advanced Chordoma | P2 | unknown | 30 | Xuanwu Hospital, Beijing | Oct 2023 | |
| NCT04559607 | TACE Combined With Camrelizumab and Apatinib in Intermediate and Advanced Hepatocelluar Carcinoma | N/A | unknown | 188 | Zhongda Hospital | Sep 2020 | |
| NCT05559008 | A Umbrella Study in R/R PTCL Guided by Molecular Subtypes | P1/P2 | unknown | 116 | Ruijin Hospital | Sep 2022 | |
| NCT05170542 | The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma. | P2 | unknown | 42 | Peking Union Medical College Hospital | Dec 2021 | |
| NCT04156698 | Induction Chemotherapy Combined With Immunotherapy for Locally Advanced Hypopharyngeal Carcinoma | P2 | unknown | 51 | Eye & ENT Hospital of Fudan University | May 2020 | |
| NCT05673577 | Camrelizumab in Combination With Cetuximab and Chemotherapy for Relapsed/Metastatic HNSCC Patients | P2 | completed | 41 | Fudan University | Mar 2023 | |
| NCT05664139 | Recombinant Human Adenovirus Type 5 Injection Combined With PD-1 Monoclonal Antibody and Nab-paclitaxel in the Treatment of Patients With Liver Metastases From Malignant Melanoma | P2 | unknown | 30 | Fujian Cancer Hospital | Feb 2023 | |
| NCT05042375 | A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer | P3 | unknown | 450 | Jiangsu HengRui Medicine Co., Ltd. | Sep 2022 | |
| NCT04978012 | Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy | P2 | unknown | 48 | Fudan University | Jul 2021 | |
| NCT04861467 | Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma | P2 | unknown | 155 | Chinese Academy of Medical Sciences | Jun 2021 | |
| NCT04674956 | A Prospective, Randomized, Double-blinded, Multi-center Clinical Trial to Evaluate the Efficiency and Safety of Anti-PD1 Antibody (Camrelizumab) Combined With Paclitaxel(Albumin Bound) and Gemcitabine as First-line Therapy in Patients With Metastatic Pancreatic Cancer | P3 | unknown | 401 | RenJi Hospital | Mar 2021 | |
| NCT04530227 | Camrelizumab With Chemotherapy in Adults With Medically Inoperable Early Stage NSCLC | P2 | unknown | 30 | Tianjin Medical University Cancer Institute and Hospital | Sep 2020 | |
| NCT04560127 | Camrelizumab in Combination With Apatinib in Patients With Radioactive Iodine-refractory Differentiated Thyroid Cancer | P2 | active not recruiting | 20 | Peking Union Medical College Hospital | Sep 2020 | |
| NCT04506138 | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | P1/P2 | unknown | 46 | Zhejiang Cancer Hospital | Aug 2020 | |
| NCT04191889 | TRIPLET | A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | P2 | unknown | 47 | Sun Yat-sen University | Apr 2020 |
| NCT06061276 | bTAE-HAIC Combined With System Therapy for Intermediate-advanced Huge HCC | N/A | recruiting | 40 | Sun Yat-sen University | May 2024 | |
| NCT06323382 | Locoregional Therapy Combined With Bevacizumab and PD1/L1 Inhibitor in Advanced Hepatocellular Carcinoma | — | recruiting | 240 | Sun Yat-sen University | Jan 2021 | |
| NCT06333561 | HAIC Combined With Lenvatinib and PD-1 Inhibitor in Infiltrative Hepatocellular Carcinoma | — | recruiting | 300 | Sun Yat-sen University | Jan 2021 | |
| NCT05713994 | CCGLC-001 | Combined HAIC, TKI/Anti-VEGF and ICIs as Conversion Therapy for Unresectable Hepatocellular Carcinoma | — | recruiting | 300 | Ze-yang Ding, MD | May 2020 |
| NCT03736863 | A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | P2 | recruiting | 147 | The First Affiliated Hospital of Zhengzhou University | Dec 2019 | |
| NCT06235164 | The Safety and Efficacy of Neoadjuvant Immunochemotherapy Followed by Laparoscopic Gastrectomy for Gastric Cancer | — | unknown | 585 | Fujian Medical University | Jan 2019 | |
| NCT06345300 | NALIRIFOX in Combination With Camrelizumab for BRPC: a Prospective, Exploratory Study | P2 | unknown | 40 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Mar 2024 | |
| NCT04143984 | Carbon-Ion Radiotherapy Plus Camrelizumab for Locally Recurrent Nasopharyngeal Carcinoma | P2 | unknown | 146 | Shanghai Proton and Heavy Ion Center | Jan 2021 | |
| NCT05461235 | Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma | P2 | unknown | 1 | China Medical University, China | Jul 2022 | |
| NCT05183958 | A Multicenter, Randomized Controlled, Phase II Clinical Study of First-line Chemotherapy and Camrelizumab With or Without Radiotherapy in the Treatment of Oligometastatic Esophageal Cancer | P2 | unknown | 118 | Zhejiang Cancer Hospital | Dec 2021 | |
| NCT05669807 | Camrelizumab Combined With Irinotecan or Albumin Paclitaxel for Second-line Treatment of Advanced Gastric Cancer | P2 | unknown | 184 | Zhejiang Cancer Hospital | Dec 2022 | |
| NCT06109207 | Neoadjuvant Camrelizumab With Dalpiciclib for Resectable Head and Neck Squamous Cell Carcinomas | P1 | recruiting | 6 | West China Hospital | Oct 2023 | |
| NCT05184946 | Clinical Study of Camrelizumab Combined With SOX in the Adjuvant Treatment of Advanced Gastric Adenocarcinoma or Gastric Esophageal Junction Adenocarcinoma | P2 | unknown | 72 | The Second Affiliated Hospital of Shandong First Medical University | Oct 2021 | |
| NCT06231680 | RCCEP | Thalidomide Prevention or Treatment of Camrelizumab-induced Reactive Cutaneous Capillary Endothelial Proliferation (RCCEP) | P2 | unknown | 132 | Henan Cancer Hospital | Jan 2024 |
| NCT05547737 | NSCLC | Multicenter, Prospective, Real World Study of Camrelizumab in Cross-line Treatment of Non-small Cell Lung Cancer | — | unknown | 500 | Henan Cancer Hospital | Sep 2022 |
| NCT05549466 | Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPC | P2 | unknown | 84 | Sun Yat-sen University | Oct 2022 | |
| NCT05532527 | NSCLC | Efficacy and Safety of Microwave Ablation Combined With Camrelizumab and Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer: a Multicenter, Open, Prospective Study | N/A | unknown | 35 | Henan Provincial People's Hospital | Sep 2022 |
| NCT04947956 | Camrelizumab in Patients With Unresectable Hepatocellular Carcinoma | — | unknown | 1,000 | Shanghai Zhongshan Hospital | Sep 2021 | |
| NCT04781686 | Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric Cancer | P2 | unknown | 35 | Zhou Fuxiang | May 2021 | |
| NCT04619433 | A Study to Evaluate SHR-1210 in Combination With Famitinib Plus Chemotherapy in Subjects With NSCLC. | P3 | terminated | 48 | Jiangsu HengRui Medicine Co., Ltd. | Feb 2021 | |
| NCT05011227 | Camrelizumab and Chemotherapy Combined With Endoscopic Surgery for Recurrent Nasopharyngeal Carcinoma | P2 | unknown | 100 | Eye & ENT Hospital of Fudan University | Aug 2021 | |
| NCT04514081 | The Clinical Trial of Chidamide+Decitabine+Camrelizumab Versus Decitabine+Camrelizumab in Anti-PD-1 Antibody Resistant Patients With Classical Hodgkin Lymphoma. | P2 | unknown | 200 | Chinese PLA General Hospital | Aug 2020 | |
| NCT06170697 | Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma | P2 | unknown | 46 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Mar 2023 | |
| NCT04889768 | HIPEC Combined With Camrelizumab, Paclitaxel and S-1 for Conversion Therapy in Patients With Advanced Gastric Cancer With Peritoneal Metastasis | N/A | unknown | 46 | Zhejiang Cancer Hospital | Jul 2021 | |
| NCT04932187 | Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 3) | P1 | unknown | 20 | Ruijin Hospital | Aug 2021 | |
| NCT04454905 | Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II Study | P2 | unknown | 50 | Sun Yat-sen University | Aug 2020 | |
| NCT05410847 | Nab-paclitaxel Plus Camrelizumab and S-1 Conversion Therapy for Gastric Cancer With Positive Exfoliative Cancer Cells | P2 | unknown | 30 | Hebei Medical University | Jun 2022 | |
| NCT05031949 | CCGLC-003 | Hyperbaric Oxygen Therapy Combined Camrelizumab in Patients With Advanced/Metastatic Hepatocellular Carcinoma | P1 | unknown | 20 | Zhang Bi Xiang, MD | Oct 2021 |
| NCT05218889 | Surufatinib Plus Camrelizumab and AS in First Line Treatment of Advanced Metastatic Pancreatic Cancer | P1/P2 | recruiting | 90 | Chinese PLA General Hospital | Aug 2021 | |
| NCT04888429 | CAPSTONE | Camrelizumab Plus Famitinib as Treatment in Patient With Advanced or Metastatic Pulmonary Sarcomatoid Carcinoma | P2 | recruiting | 28 | Qian Chu | Jul 2021 |
| NCT04907344 | TNBC | Study of Camrelizumab Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | P2/P3 | unknown | 420 | Tianjin Medical University Cancer Institute and Hospital | Jun 2021 |
| NCT04888806 | A Trial of Camrelizumab Combined With Microwave Ablation and Chemotherapy in the Treatment of Colorectal Cancer Liver Metastasis/Pulmonary Metastasis | P2 | unknown | 37 | Harbin Medical University | Jun 2021 | |
| NCT04749394 | A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With Chemoradiotherapy | P2 | unknown | 42 | Chinese Academy of Medical Sciences | Mar 2021 | |
| NCT05156970 | Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC | P2 | completed | 81 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Jun 2021 | |
| NCT05313282 | TRIPLET-III | A Trial of Hepatic Arterial Infusion Combined With Apatinib and Camrelizumab Versus Apatinib and Camrelizumab for C-staged Hepatocellular Carcinoma in BCLC Classification | P3 | unknown | 140 | Sun Yat-sen University | Jun 2022 |
| NCT05637268 | Carrelizumab Combined With Chemotherapy for Adjuvant Therapy of Esophageal Squamous Cell Carcinoma | P2 | unknown | 23 | Tianjin Medical University Cancer Institute and Hospital | Nov 2020 | |
| NCT04483284 | Study of TACE Combined With Camrelizumab in the Treatment of HCC Patients | P2 | active not recruiting | 28 | Shanghai Zhongshan Hospital | Jun 2020 | |
| NCT04405154 | A Study of Concomitant Camrelizumab With Chemoradiation for Locally Advanced Head and Neck Cancer | P2 | unknown | 32 | West China Hospital | Jun 2020 | |
| NCT05380986 | Camrelizumab Combined With Apatinib Mesylate | N/A | unknown | 500 | Henan Cancer Hospital | May 2022 | |
| NCT05839197 | CCGLC-010 | A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCC | P2 | unknown | 38 | Wan-Guang Zhang | May 2023 |
| NCT05322499 | Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer | P2 | unknown | 80 | Zhejiang Cancer Hospital | Apr 2022 | |
| NCT04318730 | Phase II Study for Combination of Camrelizumab and Apatinib in the Second-line Treatment of Recurrent or Metastatic Adrenocortical Carcinoma | P2 | recruiting | 21 | West China Hospital | Oct 2020 | |
| NCT05583383 | A Study of the Advanced Adenocarcinoma of Stomach and Gastroesophageal Junction With Camrelizumab+SOX Control Camrelizumab+SOX+ Trastuzumab | N/A | unknown | 62 | Henan Cancer Hospital | Mar 2022 | |
| NCT05189184 | HNSCC | Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell Carcinoma | P2 | unknown | 30 | The First Affiliated Hospital of Zhengzhou University | Mar 2022 |
| NCT04195828 | Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer | P2 | completed | 106 | Fujian Medical University | Jun 2020 | |
| NCT04782765 | Phase Ⅱ Trial of Camrelizumab in Patients Without Distant Metastasis Nasopharyngeal Carcinoma | P2 | unknown | 59 | Tianjin Medical University Cancer Institute and Hospital | Mar 2021 | |
| NCT04828395 | F&C | Fluzoparib Combined With Camrelizumab for Maintenance Treatment of Locally Advanced Non-small Cell Lung Cancer | P2 | unknown | 65 | Tianjin Medical University Cancer Institute and Hospital | Mar 2021 |
| NCT05236699 | CCGLC-005 | A Clinical Study of DEB-TACE Combined With Surufatinib and Camrelizumab in the Treatment of Inoperable or Metastatic ICC | P2 | completed | 23 | Tongji Hospital | Feb 2022 |
| NCT05193292 | Camrelizumab Combined With Trastuzumab and Chemotherapy in Patients With HER2-positive Advanced Colorectal Cancer | P2 | unknown | 77 | Fudan University | Jan 2022 | |
| NCT04425135 | Camrelizumab Combined With Apatinib Mesylate and Standard Chemotherapy (Pemetrixed + Carboplatin) in Patients With Tyrosine Kinase Inhibitor Failure in ALK-positive Advanced NSCLC | P2 | unknown | 59 | The First Affiliated Hospital of Xiamen University | Jul 2020 | |
| NCT04510610 | Camrelizumab Plus Decitabine in Anti-PD-1 Treatment-naive Patients With Relapsed/Refractory Classical Hodgkin Lymphoma | P2/P3 | unknown | 100 | Chinese PLA General Hospital | Sep 2019 | |
| NCT05760430 | The Synergistic Effect of Portal Venous Supply Control and Immunotherapy in Hepatocellular Carcinoma | P2 | unknown | 40 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Dec 2022 | |
| NCT05564897 | Oncolytic Adenovirus Combined With PD-1 Inhibitor in Patients With Non-muscle-invasive Bladder Cancer | P2 | unknown | 25 | Zhejiang Cancer Hospital | Aug 2022 | |
| NCT05093140 | CREDIT | Camrelizumab Plus R-CHOP Regimen in Untreated Primary Extranodal DLBCL | P2 | unknown | 30 | Sun Yat-sen University | Jun 2022 |
| NCT05234905 | H101 Combined With Camrelizumab for Recurrent Cervical Cancer | P2 | unknown | 55 | Zhejiang Cancer Hospital | Mar 2022 | |
| NCT05717738 | CCGLC-008 | Combined TACE, TKI/Anti-VEGF and ICIs as Conversion Therapy for Advanced Hepatocellular Carcinoma | — | recruiting | 300 | Tongji Hospital | Jan 2022 |
| NCT05142865 | Camrelizumab Combined With Chemotherapy and Apatinib for Extrapulmonary Neuroendocrine Carcinomas | P2 | unknown | 30 | Huazhong University of Science and Technology | Jan 2022 | |
| NCT04848454 | Efficacy and Safety of Combinition of Camrelizumab in Second-line Neoadjuvant Chemotherapy and Adjuvant Therapy | P2 | unknown | 30 | Peking University First Hospital | Nov 2021 | |
| NCT04974944 | First-line Treatment With Camrelizumab + Apatinib Versus Chemotherapy + Bevacizumab in Advanced Cervical Cancer | P2 | unknown | 172 | Sun Yat-sen University | Jul 2021 | |
| NCT04706598 | Safety and Efficacy of Camrelizumab for High-risk NMIBC Failing BCG Treatment | P1/P2 | active not recruiting | 25 | Fudan University | Jun 2021 | |
| NCT05062837 | Hepatectomy Combined With Camrelizumab and Apatinib in CNLC Stage IIIb HCC | P2/P3 | unknown | 62 | Guangxi Medical University | Jun 2021 | |
| NCT04850040 | A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin | P2 | unknown | 15 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | May 2021 | |
| NCT05085626 | Fluzoparib in Combination With Chidamide or Camrelizumab for HRD Positive HER2 Negative Advanced Breast Cancer | P2 | unknown | 40 | Tianjin Medical University Cancer Institute and Hospital | Feb 2021 | |
| NCT04609176 | SHR-1210 | Study of Camrelizumab (SHR-1210) and Apatinb Based Therapies for Alpha-fetoprotein (AFP)-Producing Gastric Cancer or Gastroesophageal Junction Adenocarcinoma | P2 | unknown | 64 | Peking University | Nov 2020 |
| NCT04070040 | PCNSL | Camrelizumab for Patients with Recurrent Primary Central Nervous System Lymphoma (PCNSL) | P2 | recruiting | 21 | Beijing Sanbo Brain Hospital | Feb 2020 |
| NCT05742750 | A Phase Ib/II Clinical Study of Camrelizumab and Apatinib Plus GP in the Treatment of Advanced Biliary Tract Cancer | P1/P2 | unknown | 48 | Sun Yat-sen University | Mar 2023 | |
| NCT04793139 | Efficacy and Safety of Camrelizumab in Real-World Prospective Study | — | unknown | 1,000 | Guangdong Association of Clinical Trials | Apr 2021 | |
| NCT05650216 | Camrelizumab Combined With Neoadjuvant Concurrent Chemoradiotherapy for Resectable Locally Advanced ESCC（NICE-RT） | P2 | unknown | 50 | Shanghai Chest Hospital | Dec 2022 | |
| NCT05135364 | HAIC Combined With Camrelizumab and TKI for Unresectable Hepatocellular Carcinoma After TACE Failure | P2 | unknown | 48 | Yue Han | Nov 2021 | |
| NCT04074564 | MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue Sarcoma | Early P1 | unknown | 60 | HRYZ Biotech Co. | Nov 2019 | |
| NCT05385185 | Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer | P2 | unknown | 20 | Hebei Medical University | May 2022 | |
| NCT05476380 | Neoadjuvant Therapy of Camrelizumab Combined With Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma | P2 | unknown | 39 | Tianjin Medical University Cancer Institute and Hospital | Feb 2021 | |
| NCT07053215 | Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC | N/A | completed | 60 | The First Hospital of Hebei Medical University | Dec 2020 | |
| NCT05367687 | HCC | A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) Versus Camrelizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | P2 | completed | 251 | Jiangsu HengRui Medicine Co., Ltd. | Sep 2022 |
| NCT05088057 | Neoadjuvant Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer | P2 | unknown | 30 | Aiping Shi | Sep 2021 | |
| NCT04884906 | Camrelizumab Combined With Radiotherapy and Chemotherapy for the Treatment of Recurrent or Metastatic Cervical Cancer | P2 | unknown | 40 | Tianjin Medical University Cancer Institute and Hospital | Nov 2020 | |
| NCT05643417 | Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard Therapy | P1 | unknown | 80 | Fudan University | Dec 2022 | |
| NCT05724355 | CDK4/6 Inhibitor Plus Camrelizumab for PD-1 Inhibitor Refractory R/M NPC | P2 | unknown | 32 | Sun Yat-sen University | Sep 2022 | |
| NCT05097248 | Camrelizumab in Combination With PLD and Losartan in Patients With TNBC Who Have Received ≦ 1 Line of Chemotherapy | P2 | unknown | 52 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Oct 2021 | |
| NCT04701060 | Camrelizumab Combined With Apatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma | P2 | completed | 31 | Tianjin Medical University Cancer Institute and Hospital | Jan 2021 | |
| NCT05330065 | A Study of Intrapleural Administration of Bevacizumab and Camrelizumab for Malignant Pleural Effusion | P1/P2 | unknown | 55 | The First Affiliated Hospital of Zhengzhou University | Aug 2022 | |
| NCT04390945 | Camrelizumab Combined With CRT for Treatment of Patients With Local Recurrence of Esophageal Cancer | P2 | unknown | 62 | The First Affiliated Hospital of Henan University of Science and Technology | Dec 2021 | |
| NCT05005468 | CAMFA-L | A Phase II Trial of Camrelizumab Combined With Famitinib for Adjuvant Treatment of Stage II-IIIA NSCLC. | P2 | unknown | 61 | Shanghai Chest Hospital | Sep 2021 |
| NCT04724226 | C-couple | Cryoablation Combined With Camrelizumab and Apatinib in Advanced Hepatocellular Carcinoma | P2 | unknown | 34 | Sun Yat-sen University | Sep 2021 |
| NCT04443309 | Lenvatinib in Combination With Camrelizumab as First-Line Therapy in Patients With Advanced HCC | P1/P2 | unknown | 53 | Peking Union Medical College Hospital | Sep 2020 | |
| NCT05051865 | To Explore the Efficacy and Safety of Camrelizumab Combined With SHR1020 in the Treatment of Advanced Melanoma | P2 | unknown | 60 | Peking University Cancer Hospital & Institute | Oct 2021 | |
| NCT04649476 | NEOPBOSCC | Neoadjuvant PD-1 Blockade in Resectable Oral Squamous Cell Carcinoma | P2 | completed | 68 | Hospital of Stomatology, Wuhan University | Mar 2021 |
| NCT04510818 | Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 2) | P1 | unknown | 20 | Ruijin Hospital | Aug 2020 | |
| NCT04508686 | Combination of Metronomic Capecitabine With Camrelizumab for Treatment of Refractory Solid Tumor Trial (Cohort 1) | P1 | unknown | 20 | Ruijin Hospital | Aug 2020 | |
| NCT05490485 | Camrelizumab Combined With Cisplatin in the Treatment of Advanced Cutaneous Squamous Cell Carcinoma | P2 | unknown | 20 | Henan Cancer Hospital | Aug 2022 | |
| NCT04510064 | Conversion Effects of PD-1 Antibody Camrelizumab Combined With Nab-POF Regimen Chemotherpy in Patients With Initially Unresectable Locally Advanced or Limited Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma：FDZL-GC001 Trial | P2 | completed | 40 | Fudan University | Jan 2021 | |
| NCT05189483 | Albumin-bound Paclitaxel Plus Camrelizumab for Advanced Soft Tissue Sarcoma. | P2 | unknown | 40 | Henan Cancer Hospital | Jan 2022 | |
| NCT04970043 | Camrelizumab Combined With Pemetrexed and Carboplatin for the Study of EGFR-mutated Lung Squamous NSCLC Treatment | N/A | unknown | 58 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Jul 2021 | |
| NCT05438706 | A Clinical Study of the Efficacy and Safety of Chidamide in Combination With Camrelizumab and Carboplatin or Capecitabine in the Second and Third Line Treatment of Relapsed/Metastatic Triple-negative Breast Cancer | P2 | unknown | 70 | Fudan University | Jul 2022 | |
| NCT05003700 | Hepatic Arterial Infusion Combined With Lenvatinib and Camrelizumab for Unresectable Hepatocellular Carcinoma | P2 | completed | 39 | Nanfang Hospital, Southern Medical University | Aug 2021 | |
| NCT05111444 | GEJ | Camrelizumab Plus Pyrotinib Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | P2 | unknown | 65 | Fudan University | Dec 2021 |
| NCT05320081 | Camrelizumab Combined With CD30 CAR-T in the Treatment of Relapsed/Refractory CD30+ Lymphoma | P2 | unknown | 30 | Huazhong University of Science and Technology | Nov 2021 | |
| NCT04930315 | CAPT | SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma | P2 | unknown | 78 | Zhejiang University | Sep 2021 |
| NCT04929652 | Surufatinib Combine With Immunotherapy and Chemotherapy for Second-line Treatment in Advanced Colorectal Cancer | P1/P2 | unknown | 48 | Jiangsu Cancer Institute & Hospital | Jun 2021 | |
| NCT04683198 | Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC | P2 | unknown | 69 | Chinese Academy of Medical Sciences | Apr 2021 | |
| NCT04782089 | Study of PD-1 Antibody and PARP Inhibitor in Extensive Stage Small Cell Lung Cancer | N/A | unknown | 20 | Qilu Hospital of Shandong University | May 2021 | |
| NCT04866862 | Fruquitinib Combined With Camrelizumab in Non MSI-H/dMMR Refractory Colorectal Cancer | P2 | unknown | 32 | The First Affiliated Hospital with Nanjing Medical University | Apr 2021 | |
| NCT05339581 | iPLENTY-pvtt | IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation | N/A | unknown | 78 | RenJi Hospital | May 2022 |
| NCT05099848 | A Trial of Conversion Treatment of HAIC Combined With Camrelizumab and Apatinib for Unresected Hepatocellular Carcinoma | P2 | completed | 21 | Shandong Cancer Hospital and Institute | Mar 2021 | |
| NCT04609293 | Observational Study of Camrelizumab Combined With Apatinib and Hyperfractionated Radiotherapy for Renal Cell Carcinoma | — | unknown | 30 | Peking University First Hospital | Oct 2020 | |
| NCT04888611 | Neoadjuvant PD-1 Antibody Alone or Combined With DC Vaccines for Recurrent Glioblastoma | P2 | unknown | 40 | Huashan Hospital | Oct 2021 | |
| NCT04832204 | Apatinib Combined With SHR-1210 as Second-line Treatment in Solid Tumors With Only Liver Metastases | P2 | unknown | 20 | Beijing Hospital | Mar 2021 | |
| NCT05114707 | Camrelizumab Plus Chemoradiotherapy for Patients With Locoregional Cancer of Nasal Cavity and Paranasal Sinuses | P2 | unknown | 57 | Sun Yat-sen University | Apr 2021 | |
| NCT04282278 | Study of Anti-PD-1 Antibody Multimodal Combination as First-line Treatment on Time Window of Advanced Solid Tumor | P2 | unknown | 180 | Hebei Medical University Fourth Hospital | Jul 2020 | |
| NCT05355168 | Neoadjuvant CRT Combined With Camrelizumab and Nimotuzumab for Initially Inoperable Patients With Esophageal Carcinoma | P2 | completed | 35 | Anhui Provincial Hospital | Nov 2021 | |
| NCT05070598 | Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer | P2 | unknown | 35 | Shengjing Hospital | Sep 2021 | |
| NCT04606108 | Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of High-risk Soft Tissue Sarcoma | P2 | unknown | 62 | Sun Yat-sen University | Oct 2020 | |
| NCT05290935 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy: Multi-Center Trial | P2 | unknown | 122 | Lei Li | Mar 2022 | |
| NCT04613674 | TNBC | A Study of Camrelizumab Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) | P3 | completed | 441 | Jiangsu HengRui Medicine Co., Ltd. | Dec 2020 |
| NCT05600998 | A Study of Camrelizumab in Combination With Anlotinib in Subjects Advanced Ovarian Clear Cell Carcinoma | N/A | unknown | 20 | Peking University Third Hospital | Oct 2022 | |
| NCT04676997 | TNBC | Neoadjuvant Study of Camrelizumab Plus Chemotherapy in Triple Negative Breast Cancer (TNBC) | P2 | unknown | 20 | Shandong Cancer Hospital and Institute | May 2020 |
| NCT05550025 | TACE Combined With Camrelizumab and Apatinib in the Treatment of Advanced Liver Cancer | P2 | unknown | 26 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Dec 2021 | |
| NCT04221516 | Camrelizumab After Completion of Radiotherapy for Oligometastatic Nasopharyngeal Carcinoma | P2 | unknown | 52 | Nanfang Hospital, Southern Medical University | Jan 2020 | |
| NCT05001412 | Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of ES-SCLC | P1 | unknown | 36 | Zhou Chengzhi | Jan 2021 | |
| NCT05441254 | Camrelizumab Combined With Intraperitoneal Infusion of Nab-paclitaxel, Intravenous Chemotherapy and S-1 in the Treatment of Advanced Gastric Cancer With Peritoneal Metastasis：Single-arm, Prospective Clinical Study | P2 | unknown | 33 | Zhongshan Hospital Xiamen University | Jul 2022 | |
| NCT04984018 | Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade | P2 | unknown | 73 | The First Affiliated Hospital of Zhengzhou University | Dec 2021 | |
| NCT05050760 | DCF Combined With Camrelizumab in the Treatment of Esophageal Cancer | N/A | unknown | 55 | Xijing Hospital | Sep 2021 | |
| NCT04479527 | Evaluation Effectiveness and Safety of (cTACE or DEB-TACE + FOLFOX Regimen HAIC) Combined With Camrelizumab and Apatinib Mesylas in the Treatment of Advanced Hepatocellular Carcinoma | P2 | unknown | 34 | Peking University Cancer Hospital & Institute | Apr 2021 | |
| NCT05171309 | Camrelizumab in Combination With Apatinib Plus NK Cell for Advanced HCC | P2 | unknown | 35 | Nanfang Hospital, Southern Medical University | Jan 2021 | |
| NCT04631757 | GEJ | Conversion Therapy of Camrelizumab Plus Chemoradiotherapy in Participants With Initial Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma | P2 | unknown | 33 | Tianjin Medical University Cancer Institute and Hospital | Dec 2020 |
| NCT04612894 | Camrelizumab and Apatinib for Neoadjuvant Therapy in Thyroid Cancer | P2 | unknown | 31 | Fudan University | Dec 2020 | |
| NCT04583020 | Neoadjuvant PD-1 in Newly Diagnosed Glioblastoma | P2 | unknown | 42 | Peking Union Medical College Hospital | Nov 2020 | |
| NCT04593485 | Anti-PD-1 Antibody in the Treatment of Patients With Malignant Melanoma of the Female Genital Tract | P2 | unknown | 40 | Fudan University | Oct 2020 | |
| NCT04426955 | SHR-1210 | Study of Camrelizumab (SHR-1210) in Combination With Concurrent Chemoradiotherapy in Locally Advanced Esophageal Cancer | P3 | unknown | 396 | Jiangsu HengRui Medicine Co., Ltd. | Jun 2020 |
| NCT04440917 | IMplus | Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma | P2 | unknown | 32 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Jun 2020 |
| NCT04365049 | Nab-Paclitaxel and Gemcitabine Plus Camrelizumab and Radiotherapy for Locally Advanced Pancreatic Adenocarcinoma | — | unknown | 100 | Sun Yat-sen University | Apr 2020 | |
| NCT05472467 | IMCORT-2 | Camrelizumab Combination With SBRT and Concurrent Chemotherapy Treated Stage IV Oligometastatic Non-small Cell Lung Cancer | P2 | unknown | 35 | Sichuan Cancer Hospital and Research Institute | Dec 2021 |
| NCT05151549 | A Study of Carilizumab Combined With Concurrent Chemoradiotherapy | P2 | unknown | 46 | Hunan Cancer Hospital | Dec 2021 | |
| NCT04587817 | Combination of Hyperfractionated Radiotherapy With Immunotherapy in Massive Tumors | — | unknown | 60 | Peking University First Hospital | Oct 2020 | |
| NCT04342936 | SHR-1210 | Study of Camrelizumab (SHR-1210) vs. Chemotherapy in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma | P3 | unknown | 56 | Jiangsu HengRui Medicine Co., Ltd. | Jul 2020 |
| NCT04910126 | Camrelizumab Plus Doxorubicin for the First Line Treatment of Adcanced Soft Tissue Sarcoma | P2 | unknown | 84 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Nov 2020 | |
| NCT04393506 | Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma | P1 | completed | 21 | Shanghai Jiao Tong University School of Medicine | Apr 2020 | |
| NCT05342389 | Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer | P2 | unknown | 68 | Sixth Affiliated Hospital, Sun Yat-sen University | May 2022 | |
| NCT04338620 | Camrelizumab Combined With Albumin-bound Paclitaxel and Platinum in Neoadjuvant Treatment of Resectable NSCLC | P2 | unknown | 94 | Tang-Du Hospital | Apr 2020 | |
| NCT04878107 | SABRE | SBRT/LDRT in Combination With Camrelizumab and Apatinib in Metastatic Non-small Cell Lung Cancer Patient Previously Treated With PD-1/L1 Inhibitor and Chemotherapy | P2 | unknown | 88 | Wuhan University | Mar 2022 |
| NCT04547088 | Camrelizumab Combined With Apatinib in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | P2 | unknown | 27 | Sun Yat-sen University | Sep 2020 | |
| NCT04548271 | Camrelizumab Combined With Apatinib in Patients With PD-1 Antagonists Resistant Recurrent/Metastatic Nasopharyngeal Carcinoma | P2 | unknown | 25 | Sun Yat-sen University | Sep 2020 | |
| NCT05042336 | The Effectiveness and Safety of Camrelizumab/Lenvatinib Combined With TACE in Patients With Borderline Resectable HCC | P1/P2 | unknown | 49 | Sichuan University | Sep 2021 | |
| NCT05095636 | Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer | P2 | unknown | 102 | Fudan University | Mar 2021 | |
| NCT04625803 | Neoadjuvant Therapy for Locally Advanced Colon Cancer | P2 | completed | 64 | Zhejiang University | Jan 2021 | |
| NCT04541251 | Neoadjuvant Camrelizumab, Nab-paclitaxel and Carboplatin in Stage IB-IIIA NSCLC | P2 | unknown | 40 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Aug 2020 | |
| NCT04231552 | Preoperative Short Course Radiotherapy With Chemotherapy and Camerelizumab in Locally Advanced Rectal Cancer | P1/P2 | unknown | 30 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Nov 2019 | |
| NCT04294511 | Study of Camrelizumab in Combination With Neoadjuvant Chemotherapy in the Treatment of Osteosarcoma | P2 | unknown | 75 | Sun Yat-sen University | Dec 2019 | |
| NCT04586088 | Apatinib and Camrelizumab in Recurrent or Metastatic Nasopharyngeal Carcinoma With First-line Treatment Failure | P2 | unknown | 58 | Sun Yat-sen University | May 2020 | |
| NCT05670925 | A Trial Exploring the Opportune Administration of Nab-paclitaxel in the First Line Treatment, Camrelizumab Combined With Nab-paclitaxel and Famitinib, of TNBC. | P2 | unknown | 46 | Fudan University | Mar 2023 | |
| NCT04741490 | Camrelizumab Combined With Radiotherapy for Adjuvant Treatment of Esophageal Squamous Cell Carcinoma After Surgery | N/A | unknown | 20 | Fuzhou General Hospital | Feb 2021 | |
| NCT04303741 | A Phase II Trial of Camrelizumab in Combination With Apatinib and Eribulin in Patients With Advanced TNBC | P2 | unknown | 46 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Mar 2020 | |
| NCT04826406 | A Study of Camrelizumab Combined Apatinib in Hepatocellular Carcinoma Previously Treated With Immune Checkpoint Inhibitors (ICIs). | P2 | unknown | 40 | Hunan Cancer Hospital | Feb 2021 | |
| NCT05208177 | A Study of SHR-1802 in Patients With Advanced Solid Tumor | P2 | terminated | 25 | Jiangsu HengRui Medicine Co., Ltd. | Apr 2022 | |
| NCT04979585 | Camrelizumab Plus Amlotinib and Chemotherapy in the First-line Treatment of Melanoma | P2 | unknown | 66 | Di Wu | Jul 2021 | |
| NCT04948125 | Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma | P2 | unknown | 20 | Henan Cancer Hospital | Apr 2021 | |
| NCT04420130 | A Trial of Camrelizumab Combined With Ablation and Chemotherapy in Patients With Pancreatic Cancer Liver Metastasis（SHR-1210-HLJ-009） | N/A | withdrawn | 0 | Yanqiao Zhang | Aug 2020 | |
| NCT04476459 | Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL | P1/P2 | unknown | 33 | Huiqiang Huang | Jul 2020 | |
| NCT05214976 | A Trial of Camrelizumab for Injection in Combination With Famitinib Malate Capsule and Paclitaxel For Injection(Albumin Bound) in Advanced Solid Tumors of Patients | P2 | unknown | 64 | Jiangsu HengRui Medicine Co., Ltd. | Aug 2022 | |
| NCT04564313 | Safety and Efficacy of Camrelizumab (Anti-PD-1 Antibody) in Recurrent HCC After Liver Transplantation | P1 | unknown | 20 | Third Affiliated Hospital, Sun Yat-Sen University | Sep 2020 | |
| NCT04459078 | Clinical Study of Camrelizumab Combined With APatinib and Albumin Paclitacxel in Patients With Advanced Lung Adenocarcinoma | P2 | unknown | 63 | Hunan Cancer Hospital | Aug 2020 | |
| NCT04627012 | Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma | — | completed | 600 | Sun Yat-sen University | Jan 2018 | |
| NCT05545436 | PD-1 | Carrelizumab (PD-1) Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Gastric Cancer | P2 | unknown | 34 | Third Affiliated Hospital, Sun Yat-Sen University | Sep 2022 |
| NCT05198817 | A Trial of SHR-2002 Injection or Combined With Other Anti-cancer Medication in Advanced Malignant Tumors of Patients | P1 | unknown | 240 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Feb 2022 | |
| NCT05049681 | Study of Anti-PD-1 Antibody SHR-1210 Plus Apatinib vs SHR-1210 as Second-Line Treatment of Advanced Esophageal Squamous Cell | P3 | unknown | 234 | Feng Wang | Dec 2021 | |
| NCT05265793 | Camrelizumab Combined With Apatinib in the Treatment of Advanced Sarcomatoid Carcinoma or Carcinosarcoma | P2 | unknown | 45 | Fudan University | Nov 2021 | |
| NCT04625894 | The Combination of Immunotherapy and Stereotactic Ablative Radiotherapy in Oligometastatic Gastrointestinal Cancer | P1 | unknown | 21 | Fudan University | Dec 2020 | |
| NCT04453930 | A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC） | P2 | unknown | 60 | Peking Union Medical College Hospital | Jun 2020 | |
| NCT05611463 | CHANCE | Camrelizumab Plus Docetaxel and Cisplatin in Recurrent or Metastatic Oral Squamous Cell Carcinoma Patients | P2 | unknown | 25 | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | Jun 2020 |
| NCT05222035 | PD-1 Inhibitor Plus G-CSF in Recurrent/Metastatic NPC With First-line Treatment Failure | P2 | unknown | 68 | Sun Yat-sen University | Jan 2022 | |
| NCT04415385 | The Combination of Camrelizumab and Apatinib as Second-line Therapy for Advanced Pancreatic Carcinoma | P2 | unknown | 48 | Zhejiang Cancer Hospital | Jun 2020 | |
| NCT04367025 | Efficacy and Safety of Perioperative Chemotherapy Plus PD-1 Antibody in Gastric Cancer | P2 | unknown | 70 | Chinese PLA General Hospital | May 2020 | |
| NCT04720131 | Camrelizumab Combined With Apatinib and Capecitabine in Patients With Advanced Biliary Tract Cancer. | P2 | completed | 28 | Beijing Friendship Hospital | Jan 2021 | |
| NCT04974827 | A Study of Camrelizumab Combined With Concurrent Chemoradiation in Patients With Cervical Cancer | P2 | unknown | 46 | Hunan Cancer Hospital | May 2021 | |
| NCT04694183 | The Conversion Therapy of Chemotherapy Plus Camrelizumab in Metastatic Gastric Cancer | P2 | completed | 37 | Quan Wang | Aug 2020 | |
| NCT04866381 | An Exploratory Clinical Study of SHR6390 and SHR1020 in the Treatment of Esophageal Squamous Cell Carcinoma After Progression on PD-1 Antibody | P2 | unknown | 87 | Tianjin Medical University Cancer Institute and Hospital | Apr 2021 | |
| NCT04805736 | Microwave Ablation Combined With Camrelizumab in the Treatment of Early Breast Cancer | P2 | completed | 60 | The First Affiliated Hospital with Nanjing Medical University | Mar 2021 | |
| NCT04901754 | CAMERA | Camrelizumab Plus Apatinib as Maintenance Therapy in Extensive-stage Small-cell Lung Cancer | P2 | unknown | 38 | Henan Cancer Hospital | Jul 2021 |
| NCT04782622 | The Combination of Apatinib and Camerlizumab for Advanced Lung Cancer Patients With Muti-line Therapy | — | unknown | 60 | The Affiliated Hospital of Qingdao University | Mar 2021 | |
| NCT04767295 | ESCC | A Study of Camrelizumab Combined With Chemotherapy as Neoadjuvant Therapy in Adcanced Esophageal Squamous Cell Carcinoma (ESCC) | P2 | unknown | 28 | Hunan Cancer Hospital | Mar 2021 |
| NCT04286958 | ESCC | A Study of Camrelizumab As Consolidation Therapy After Radical Concurrent Chemoradiotherapy In Locally Advanced ESCC | P2 | unknown | 40 | Hebei Medical University Fourth Hospital | Apr 2020 |
| NCT04258644 | Camrelizumab in Combination With Apatinib Mesylate, Paclitaxel-albumin and S-1 for Translational Treatment of Gastric Cancer | P2 | unknown | 30 | Beijing Friendship Hospital | Mar 2020 | |
| NCT04654403 | Study of First-line Camrelizumab With or Without Chemotherapy for Advanced Esophageal Squamous Cell Cancer | N/A | unknown | 337 | The First Affiliated Hospital of Zhengzhou University | Jan 2022 | |
| NCT04952571 | GBM | Combined Treatment of Camrelizumab and Bevacizumab for Adult Patients with Recurrent Glioblastoma (GBM) | P2 | terminated | 3 | Beijing Sanbo Brain Hospital | Jun 2021 |
| NCT04792515 | CCWSA/OAFLAG | Camrelizumab Combined With SOX and/or Apatinib for Locally Advanced Gastric Cancer | P2 | unknown | 67 | First Affiliated Hospital Xi'an Jiaotong University | Jan 2021 |
| NCT04351308 | MAPAC | Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma | P2 | unknown | 60 | Peking University People's Hospital | May 2020 |
| NCT04353479 | Combined PD1 Inhibitor and Decitabine in Elderly Patients With Relapse and Refractory Acute Myeloid Leukemia | P2 | unknown | 29 | Shanghai Jiao Tong University School of Medicine | Apr 2020 | |
| NCT04152889 | A Study to Evaluate Camrelizumab in Combination With Docetaxel +S-1 as Adjuvant Treatment Therapy in Stage III Gastric Cancer | P2 | unknown | 20 | RenJi Hospital | Apr 2020 | |
| NCT04239170 | SHR-1210 | Camrelizumab(SHR-1210) Combined With GEMOX in Patients With Relapsed or Refractory Hodgkin Lymphoma | P2 | unknown | 84 | Peking University | Jan 2020 |
| NCT04303130 | Camrelizumab Combined With Endostar for First-line Treatment in Subjects With Advanced Squamous NSCLC | P2 | unknown | 52 | Peking University Cancer Hospital & Institute | Dec 2019 | |
| NCT04201990 | CCA-MPLC | Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung Cancer | P1/P2 | unknown | 20 | ShiYue Li | Dec 2019 |
| NCT04498689 | Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer | P2 | unknown | 117 | Fudan University | Aug 2019 | |
| NCT03707509 | Phase III Study of Camrelizumab in Combination With Chemotherapy in Recurrent/Metastatic Nasopharyngeal Carcinoma | P3 | unknown | 263 | Jiangsu HengRui Medicine Co., Ltd. | Nov 2018 | |
| NCT04211090 | CAP-BRAIN | Camrelizumab With AC in Patients With Brain Metastases of Driven Gene-negative,NSCLC | P2 | unknown | 45 | Sun Yat-sen University | Jan 2020 |
| NCT05134194 | A Study of Camrelizumab in Combination With Chemotherapy Regimen Comparative Chemotherapy Regimen for Metastatic Triple-negative Breast Cancer | P3 | terminated | 1 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Jan 2022 | |
| NCT04539600 | Induction Chemotherapy Combined With Camrelizumab in Locoregionally Advanced Hypopharyngeal Cancer | P2 | unknown | 23 | Sun Yat-sen University | Nov 2020 | |
| NCT05019534 | Tolerability and Safety of Vemurafenib, Cetuximab Combined With Camrelizumab for BRAF V600E-mutated /MSS Metastatic Colorectal Cancer | P1 | unknown | 12 | West China Hospital | Aug 2021 | |
| NCT04937673 | The Neoadjuvant Treatment of Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | P2 | unknown | 40 | Peking University | Jul 2021 | |
| NCT04909866 | The Efficacy and Safety of TACE, Lenvatinib and Camrelizumab in the Treatment of BCLC Stage B/C Hepatocellular Carcinoma: a Single-arm, Single-center, Open-label Study | P2/P3 | unknown | 40 | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | Jan 2021 | |
| NCT05225844 | An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal | P2 | unknown | 150 | Harbin Medical University | Jan 2019 | |
| NCT04044378 | Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma | P1/P2 | withdrawn | 0 | Peking University People's Hospital | Aug 2019 | |
| NCT04167774 | Compass-001 | A Study to Evaluate Camrelizumab in Combination With Nb-Paclitaxel in Patients With Advanced or Metastatic NSCLC | P2 | unknown | 62 | Sun Yat-sen University | Jul 2019 |
| NCT04129996 | FUTURE-C-PLUS | A Trial of Camrelizumab in Combination With Nab-paclitaxel and Famitinib as a First Line Treatment in Patients With Unresectable Locally Advanced or Metastatic Immunomodulatory Triple Negative Breast Cancer(FUTURE-C-PLUS) | P2 | unknown | 46 | Fudan University | Oct 2019 |
| NCT04512417 | A Clinical Study Of Camrelizumab With Or Without Radiotherapy In The Treatment Of Esophageal Cancer | P2 | unknown | 63 | Zhejiang Cancer Hospital | Aug 2020 | |
| NCT04507750 | Camrelizumab Combined With Apatinib in the Treatment of Epithelial Ovarian Cancer | N/A | unknown | 40 | Qianfoshan Hospital | Aug 2020 | |
| NCT04523662 | Study on the Effectiveness and Safety of Carrelizumab Combined With Apatinib Mesylate and Radiotherapy in the Treatment of Advanced Liver Cancer | P2 | unknown | 27 | Beijing Tsinghua Chang Gung Hospital | Aug 2020 | |
| NCT04670913 | Camrelizumab Plus Apatinib for Advanced Non-Squamous NSCLC Previously Treated With First-Line Immunotherapy | P2 | unknown | 30 | Junling Li | Jun 2021 | |
| NCT04068974 | Camrelizumab /Apatinib for Recurrent Platinum-resistant Ovarian Cancer | P2 | unknown | 28 | Peking Union Medical College Hospital | Oct 2019 | |
| NCT04345783 | Efficacy and Safety of Camrelizumab for Injection, Apatinib Mesylate and Tegio for First-line Refractory Patients With Advanced Gastric Cancer | P2 | unknown | 30 | Beijing Friendship Hospital | Jan 2018 | |
| NCT04346381 | Study to Evaluate the Efficacy and Safety of Camrelizumab and Famitinib in Patients With Advanced Solid Tumor | P2 | completed | 233 | Jiangsu HengRui Medicine Co., Ltd. | Jun 2020 | |
| NCT04572542 | Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer | P1/P2 | unknown | 46 | The First Affiliated Hospital of Xiamen University | Jan 2020 | |
| NCT04203485 | PD-L1 | Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC) | P3 | unknown | 762 | Jiangsu HengRui Medicine Co., Ltd. | Jun 2020 |
| NCT04182724 | Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric Cancer | P1/P2 | unknown | 57 | Chinese PLA General Hospital | Nov 2019 | |
| NCT05106335 | A Study to Evaluate Camrelizumab Combined With Famitinib as Subsequent Therapy in Patients With Advanced NSCLC | P3 | terminated | 1 | Jiangsu HengRui Medicine Co., Ltd. | Jan 2022 | |
| NCT04188860 | Immunotherapy for Recurrent Cervical Cancer Refractory to Platinum-based Chemotherapy | P2 | completed | 34 | Lei Li | Dec 2019 | |
| NCT04102982 | MWA in NSCLC | Microwave Ablation in Combination With Camrelizumab Versus Camrelizumab in Metastatic Non-small-cell Lung Cancer | P2 | unknown | 200 | Shandong Provincial Hospital | Nov 2019 |
| NCT04490421 | Camrelizumab Combined With Apatinib, Etoposide and Cisplatin Treat Small-cell Lung Cancer. | P3 | unknown | 45 | Fuzhou General Hospital | Aug 2020 | |
| NCT04806243 | Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020） | P2 | unknown | 69 | Nanfang Hospital, Southern Medical University | May 2021 | |
| NCT04520035 | Neoadjuvant Chemotherapy With Camrelizumab in Locally Advanced Esophageal Squamous Cell | P2 | unknown | 60 | Fudan University | Aug 2020 | |
| NCT04447274 | A Study of Carilizumab in Combination With Apatinib in Subjects With Unresectable UPS and ASPS | P2 | unknown | 20 | Chinese Academy of Medical Sciences | Jul 2020 | |
| NCT04035876 | SHR-1210 | Combination Camrelizumab (SHR-1210) and Apatinib for Downstaging/Bridging of HCC Before Liver Transplant | P1/P2 | unknown | 120 | Zhejiang University | Jul 2019 |
| NCT04631146 | Efficacy and Safety of Camrelizumab in Real-World Study | — | unknown | 450 | Guangdong Association of Clinical Trials | Nov 2020 | |
| NCT04985136 | HCC | A Study of Camrelizumab Combined With Rivoceranib Mesylate Versus Investigator's Choice of Regimen in Treatment of Patients With Advanced Hepatocellular Carcinoma (HCC) | P3 | terminated | 1 | Jiangsu HengRui Medicine Co., Ltd. | Sep 2021 |
| NCT04202978 | Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer | P1/P2 | unknown | 23 | Zhongshan Hospital Xiamen University | Mar 2020 | |
| NCT04067986 | Camrelizumab Combined With Apatinib in the Treatment of Patients With Advanced Gastric Cancer and Colorectal Cancer | P1/P2 | unknown | 62 | Zhongshan Hospital Xiamen University | Aug 2019 | |
| NCT04286711 | Clinical Study of Albumin-paclitaxel Combined With Apatinib and Camrelizumab in Advanced Gastric Cancer | P1/P2 | unknown | 52 | China Medical University, China | Mar 2020 | |
| NCT03871855 | A Study of SHR-1702 Alone or With Camrelizumab in Participants With Advanced Relapsed/Refractory Solid Tumors | P1 | terminated | 8 | Jiangsu HengRui Medicine Co., Ltd. | Apr 2019 | |
| NCT04047017 | GTN | Camrelizumab Combined With Apatinib for Recurrent Resistant GTN | P2 | completed | 20 | Peking Union Medical College Hospital | Aug 2019 |
| NCT04174339 | SHR-1210 | PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer | N/A | unknown | 20 | Fujian Cancer Hospital | Dec 2019 |
| NCT04771715 | PD-1 | Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Patients With Advanced Colorectal Cancer | — | unknown | 100 | Peking Union Medical College Hospital | May 2019 |
| NCT04225364 | Efficacy of Neoadjuvant PD-1 Blockade Plus Chemotherapy for Esophageal Squamous Cell Carcinoma | P2 | completed | 56 | Guangzhou Institute of Respiratory Disease | Jan 2020 | |
| NCT04642664 | ACABC | Apatinib Plus Camrelizumab in Patients With Previously Treated Advanced Biliary Tract Cancer | P2 | completed | 22 | Peking Union Medical College Hospital | Dec 2018 |
| NCT04126993 | Study of SHR-1210 Combined With Apatinib in the Treatment of Sarcoma | P2 | unknown | 80 | Tianjin Medical University Cancer Institute and Hospital | Jun 2019 | |
| NCT03912857 | SHR-1210 | Camrelizumab(SHR-1210) Combined With Apatinib in the Treatment of Advanced Metastatic Colorectal Cancer | P2 | unknown | 50 | Sun Yat-sen University | Dec 2018 |
| NCT03099382 | Study of SHR-1210 Versus Investigator's Choice of Chemotherapy for Participants With Advanced Esophageal Cancer | P3 | completed | 457 | Jiangsu HengRui Medicine Co., Ltd. | May 2017 | |
| NCT02742935 | A Study to Evaluate the Safety and Tolerability of Using SHR-1210 by Advanced Solid Tumor Subjects | P1 | completed | 99 | Jiangsu HengRui Medicine Co., Ltd. | Apr 2016 |
Camrelizumab clinical trials: frequently asked questions
- How many Camrelizumab clinical trials are there?
- 410 Camrelizumab clinical trials are catalogued on Hipa.ai, sourced from the AACT mirror of ClinicalTrials.gov. 99 are actively recruiting participants. 28 are marked completed.
- Are Camrelizumab clinical trials recruiting in 2026?
- Yes — 99 Camrelizumab trials are actively recruiting in 2026. See the recruiting trials and the per-state site list further down this page.
- What conditions is Camrelizumab being studied for?
- Camrelizumab is being studied for Hepatocellular Carcinoma, Nasopharyngeal Carcinoma, Immunotherapy, Gastric Cancer, Esophageal Cancer and 373 more. The trials are grouped by indication on this page.
- What phase is Camrelizumab in?
- Camrelizumab clinical trials span 1 Phase 4, 44 Phase 3, 261 Phase 2, 17 Phase 1. The phase × status matrix at the top of this page breaks down counts by phase and recruitment status.
- Who sponsors Camrelizumab clinical trials?
- The lead sponsor across the most Camrelizumab trials is Sun Yat-sen University, with 139 additional lead sponsors listed in the data. Each trial row links to the full study detail page including sponsor information.
Sources and methodology
Trial inventory derived from the AACT mirror of ClinicalTrials.gov. Trials are filtered to those naming Camrelizumabas an intervention. Phase, status, enrollment, sponsor, and dates are taken from the source `studies` table; primary indication is the first listed condition. Acronyms are extracted from each trial's brief title where present. PubMed links are populated for trials whose published primary outcomes have been indexed in our evidence cache.
Last refreshed .
Related pages on Hipa.ai: